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ABSTRACT 
Purpose: The sustainability of clinical pharmacogenomics requires further study of clinical 
education on the topic, its effects on clinical workflow, and the responsibilities of different 
providers for its delivery. Tools from the discipline of implementation science were utilized 
herein to help achieve the purposes of the three studies. The broad purpose of this dissertation is 
to advance the work of clinical pharmacogenomic implementation through a more rigorous 
convergence with implementation science. 
Methods: Three studies constitute the whole of this dissertation. The first is a scoping review 
that provides a broad characterization of the methods utilized in available peer-reviewed 
literature focusing on provider use of and experience with using pharmacogenomics in practice 
or the study setting. The second study used semi-structured in-depth interviews to elicit strategies 
and perspectives from leadership in current implementation programs using the Consolidated 
Framework for Implementation Science (CFIR) Process Domain. The third used a cross-
sectional quantitative survey with experimental vignettes to explore the potential for pharmacist-
physician collaboration using newly developed implementation science outcomes. 
Results: The scoping review included 25 studies, with many focused on the interactions of 
providers with clinical decision support systems and adherence to therapeutic recommendations 
represented. Results from the interviews were extensive but several highlights included a focus 
on understanding pharmacogenomic use prior to implementation, high-touch informal 
communication with providers, and the power of the patient case. The survey analysis revealed 
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that the primary care physicians believe that it is more appropriate to deliver clinical 
pharmacogenomics when a pharmacist is physically located in a clinic and is responsible for 
managing and modifying a drug therapy based on these results. 
Conclusion: These three studies further the convergence of implementation science and genomic 
medicine, with particular focus on pharmacogenomics and the foundational concept of 
implementation science, sustainability. The scoping review should provide future researchers 
with a landscape of available and previously used methodologies for interventional 
pharmacogenomic studies. The interview results will help new implementers of 
pharmacogenomics steer around avoidable hurdles or make them easier to address. The survey 
results showcase the potential for pharmacist-physician collaboration in clinical 
pharmacogenomics. 
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INTRODUCTION 
Precision medicine origins 
In early 2015, the announcement of the Precision Medicine Initiative would make 
precision medicine a nearly ubiquitous term across all sectors of the health care industry pushing 
an innovative message. This program has since been renamed the “All of Us Research Program”, 
and focuses on gathering the genomic, environmental, and lifestyle data on over one million 
Americans across diverse populations (allofus.nih.gov).1 This National Institutes of Health (NIH) 
program represents one of the largest efforts to integrate rapidly progressing genomic 
technologies into research and accelerating medical innovation and breakthroughs. However, this 
program has been preceded by numerous academic, industry, and government driven initiatives 
pushing this science forward into clinical care.  
Prior to genomic information being utilized in clinical care there have been several public 
initiatives created to curate this complex data. One of these is ClinVar, a freely available archive 
of information at the National Center for Biotechnology Information (NCBI) on the relationships 
between genomic variants and phenotypes.2 A second program, ClinGen, was launched in 2013 
to address the clinical relevance of the genomic variants identified in ClinVar.3 With the majority 
of the 80 million genetic variants identified in the human genome having no clear link to human 
disease or health implications, it was discovered that clinical laboratories may be interpreting the 
importance of variants differently, potentially leading to inappropriate medical interventions. 
ClinGen is focused on improving how new genomic discovery is used in clinical care by 
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increasing communication between research institutions. The central questions for the project 
were: “Is this gene associated with a disease?”, “Is this variant causative?”, and “Is this 
information actionable?”.  
Concurrently developed through requests from the National Human Genome Research 
Institute (NHGRI) was the Clinical Sequencing Exploratory Research (CSER) program. This 
program was initiated to create the evidence base for what appear to be the key challenges of 
actually integrating genomic sequencing methods into clinical care across both adult and 
pediatric patients.4 Several of these investigation sites focused cancer patients or those at an 
increased risk of developing cancer, while others focused more on self-reported health patients 
and those with other medical conditions. Not only was the CSER interested in addressing the 
issues of generating genomic data and conducting the subsequent analyses, they also dedicated 
resources to understand provider level education factors, patient and family communications, the 
clinical utility of testing (ClinGen’s “Is this information actionable?”) and the ethical, legal, and 
social implications (ELSI). The ELSI has become an important area of focus in the NHGRI’s 
2020 strategic vision for genomics (https://www.genome.gov/27570607/strategic-planning-
overview/).  
While these aforementioned projects represent more sweeping initiatives related to 
genomics, there also exist several other collaborative or consortiums focused on more specific 
issues. The Electronic Medical Records and Genomics (eMERGE) Network was formed in 2007 
and focused on exploring how the electronic health record (EHR) may be married with the 
growing genomic data repositories, and how clinically relevant variants could be made 
actionable through this to support clinical decision support.5 The work of eMERGE’s diverse 
network allows for consolidation of genomic data across sites for comparison to already existing, 
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longitudinal phenotypic data from the EHR. This can lead to the discovery of novel variants in 
the population, compared then to existing variants, leading to a final determination of those 
clinically actionable and in need of being placed in the EHR.  
Genomic medicine implementation and pharmacogenomics 
The Implementing Genomics Into Practice (IGNITE) Network formed in 2013 takes the 
logical next step in preparing the clinical environment for the inevitability of integrating new 
patient-level genomic data.6  Health care research has been steadily moving towards an emphasis 
on generating more real-world evidence of new health interventions. For real-world evidence to 
actually exist, the practitioners and researchers the intervention affects must be effectively 
prepared to use it. The work of IGNITE builds on the eMERGE work through point-of-care 
integration of the data into the EHR and use of CDS tools to guide the clinician. The challenges 
to genomic medicine most targeted by the IGNITE group include those that can be classified a 
T3 and T4 translational research practices.7 These include improving patient outcomes and care 
quality, evaluating the cost of different testing approaches, enhancing provider engagement and 
education, and addressing the policy challenges of testing reimbursement and payer support.  
The diversity of genomic technologies is both a barrier and facilitator to implementation 
in clinical care. Genomic sequencing has accelerated with the development of massively parallel 
sequencing techniques, and includes sub-applications of the technology such as exome 
sequencing and multigene panels.8 Exome sequencing includes only those regions of the genome 
that code for proteins (exons), and has been used more extensively in past years because of its 
lower cost technical ability, yet there are limitations related to inadequate sequencing depths and 
identifying genotypes that exist at specific single-nucleotide polymorphisms or SNPs outside of 
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the exons.9,10 Multigene panels are typically aimed at specific genes where clinically significant 
variants are known to exist and may be expressed in certain patient. One of the most common 
historical uses of genomic sequencing has been the diagnosis of rare Mendelian disease, and is 
typically indicated for those patients with a suspected monogenic disorder.11 These diagnoses 
can help clinicians develop treatment plans and patients make personal decisions on family 
planning. Additional applications can include screenings of partners prior to the conception of 
offspring and genetic predisposition screenings for information on predictions of disease risk 
based on genetics as well, giving clinicians another layer of phenotypic data for the patient.  
Included in this last type of predisposition screening are predispositions related to 
medication efficacy and safety based on genomics, which has become known as 
pharmacogenomics. This will be the focus of the remainder of this dissertation. 
Pharmacogenomics works through the identification of variants in the genome that exert some 
influence on the effects of medication.12 Variations can occur in the absorption, distribution, 
metabolism, excretion (ADME) genes, those that affect the medication’s pharmacokinetics or the 
pharmacodynamic genes that modify the target or pathway of the medication in the body.   
 The pharmacogenomic implications for a patient can apply either to those variants 
somatically acquired, typically cancer or infectious disease, and variants originating in the 
germline DNA, that sequence with which you are born. Pharmacogenomics has been the leading 
the way in operationalizing the benefits of precision medicine. A seminal systematic review in 
2001 explored the role for pharmacogenomics in potentially reducing the number of adverse 
drug reactions, a leading cause of death then and still today.13,14 Their results showed about 60% 
of drugs cited in ADR studies at the time had at least one drug-metabolizing enzyme that was 
genetically encoded with a variant known to cause poor metabolism.  
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Metabolism classification for these enzymes encoded in the germline has become a key 
action item from patient’s specific diplotypes, one haplotype from each parent.15  The CYP450 
gene superfamily was an early pharmacogenomic discovery and is involved in the metabolism of 
about 75% of commonly prescribed drugs.16 The polymorphic drug metabolism enzymes 
associated with CYP450 genes are prone to variations that ultimately affect how a drug’s 
pharmacokinetics act upon the patient, and the subsequent safety and efficacy to the patient. The 
phenotypic definitions of the various metabolizer statuses recently reached consensus through 
work by the Clinical Pharmacogenetics Implementation Consortium (CPIC).17 We will discuss 
CPIC in greater detail below. Standardization of these terms is crucial for the reporting and 
sharing of results across laboratories and EHRs. The final terms are created based on a 
combination of allele functional status, which include increase, normal, decreased, and no 
function.18 The metabolizer terms include ultrarapid, rapid, normal, intermediate, and poor. 
Those of most interest clinically are the ultrarapid metabolizers, which include two increased 
function alleles or more than 2 normal alleles, and poor metabolizers, which include 
combinations of no function alleles and/or decreased function alleles.18 
Genotyping of tumors or infectious diseases, also known as somatic testing, is another 
way pharmacogenomics has been operationalized in precision medicine.12 An ideal state for 
‘precision medicine’ might be circumstance where every medication based treatment is 
developed specifically for a biomarker(s) known to be causing the disease. Although not there 
yet, tumor biomarkers appear to be carving a path where companion diagnostic tests can be used 
to guide the decision to use a specific anti-cancer agent targeted to a specific mutation. This is 
intended to interfere with the tumor’s function to inhibit growth and progression, leading to 
quicker resolution of the disease.19 Some of the most well-known mutations are the HER2 target 
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for breast cancer, EGFR for non-small cell lung cancer, and BRAF for melanoma.20-22 Germline 
pharmacogenomics also has a role in preventing adverse events for several commonly used 
chemotherapy agents that may require dose reductions or drug switches to avoid potentially 
devastating consequences. The TPMT, DPYD, and UGT1A1 genes are several that contain 
toxicity biomarkers variants.19   
Movement towards implementing pharmacogenomics in clinical practice, similar to 
genomics more broadly, has been driven by academic medical centers funded from public 
resources such as the NIH. Early on, after the completion of the Human Genomic Project the 
Pharmacogenomics Research Network (PGRN) began receiving grants from the National 
Institute of General Medical Sciences to study how genetic variation contributes to 
interindividual differences in responses to medication.23 The eMERGE network mentioned 
previously received grants from the NHGRI to dedicate part of their work to coupling the EMR 
with actionable pharmacogenomic data.24 Since then the number of supported collaborative, 
consortiums dedicated to facilitating the implementation of pharmacogenomics have steadily 
grown. Two highly influential, and coordinated, efforts have been The Pharmacogenomics 
Knowledgebase (PharmGKB) and CPIC, which was briefly mentioned earlier. PharmGKB 
works through a process starting with extracting knowledge from pharmacogenomic literature on 
the associations between variants and drugs to determine those to be “very important 
pharmacogenes (VIP)”. These lead to pharmacogenomic summaries based on genotypes with 
different levels of evidence.25 All this knowledge can then filter into implementation projects and 
also to CPIC, whose primary responsibility is to turn genotypes into meaningful phenotypes that 
a clinician can act on. Both PharmGKB and CPIC annotate their levels of evidence across the 
gene-drug pairs they have evaluated. The highest level of evidence for PharmGKB is level 1A, 
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which is defined as “Annotation for a variant-drug combination in a CPIC or medical society-
endorsed PGx guideline, or implemented at a PGRN site or in another major health system” 
(pharmgkb.org/page/clinAnnLevels).26 CPIC has designated its levels for gene-drug pairs as 
either: A, B, C, or D. Level A indicates that “genetic information should be used to change 
prescribing of affected drug”, while level B indicates that genetic information could be used to 
change prescribing because alternatives are likely as effective and safe as non-genetically based 
dosing. Lower levels, C and D, indicated that there are no recommended prescribing actions 
(cpicpgx.org/prioritization/#flowchart).27 CPIC uses these levels to prioritize their clinical 
prescribing guideline development, of which there are 35 currently published and more in 
progress. These guidelines are not intended to help clinicians order a test, rather how to use the 
results when they become available. More recently, the Pharmacogene Variation (PharmVar) 
consortium was formed to address the need for a more systematically maintained pharmacogene 
nomenclature (or language) system as the number of variants discovered continues to grow.28 
The work of these organizations has served as a crucial foundation for the 
implementation of pharmacogenomics in the sphere of academic medicine. Efficient and 
appropriate pharmacogenomic implementation, with a mindset of sustainability, should be the 
ultimate goal of using public resources to fund discovery such as this. Two of the networks 
discussed, IGNITE and eMERGE, are actively testing implementation strategies and sharing 
data. Additionally, PGRN organized the Translational Pharmacogenetics Project (TPP) in 2011 
with the stated goals of: harnessing multidisciplinary team expertise and institutional investment, 
implement routine gene-based drug dosing and selection, and to identify the best implementation 
and dissemination practices to address remaining barriers.29 Over a dozen metrics were reported 
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by the TPP covering everything from the triggers to prompting a test order to the estimated 
turnaround time, and the roles that different providers play in the implementation. 
The IGNITE network set up an internal working group dedicated to pharmacogenomics 
in 2015.30 This group set out with to engage both funded network sites and its affiliate members, 
some of which being non-academic. Measuring the impact of genotype-guided therapy on 
patient-related outcomes has become the central goal of the institutions involved. Spearheaded 
by the University of Florida, the group intends to share and disseminate data on effective and 
non-effective strategies from their individual projects, as well as metrics related to the health 
care costs involved in the strategy.30 In this model, more pharmacogenomically-mature 
institutions have the ability to share their best practices with newer entrants into the science, thus 
updating prior beliefs and improving the efficiency.  
Similarly to IGNITE, the eMERGE network initiated a pharmacogenomic specific 
project, eMERGE-PGx.31 The design of this project was focused on a particular strategy of 
testing known as preemptive pharmacogenomics, that is, the genotyping or sequencing of a 
patient prior to diagnosis enabling first point-of-care actionability. This technique was already 
being implemented among some institutions; however reactive testing still remained the most 
utilized.32 eMERGE-PGx had three objectives: sequence 84 proposed pharmacogenes in 9,000 
patients likely to be prescribed an implicated drug within one to three years, integrate the 
clinically-valid results into an EHR with the appropriate decision support and assess the 
outcomes, and develop a repository for those variants with unknown significance back-linked to 
the clinical phenotypes in the EHR.31 Early results from approximately 5,000 subjects showed 
96.19% of samples had a CPIC level A actionable variant. These high probabilities were also 
found in an external validation cohort of more than 1,000 patients in a tertiary medical center. A 
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novel disease-drug association tool was developed to map drugs to distinct diseases, then 
pharmacogenomically annotated. Ninety-percent of the top 21 diseases in this population and 
more than 93% of patients could be treated with more than one medication with actionable 
pharmacogenomic information.  
Many of opportunities afforded to the implementers of pharmacogenomics, and noted 
successes, were enabled by high levels clinical and leadership support at the institution, as well 
as extensive external funding. The next frontier in the implementation of pharmacogenomics is 
to address the unique challenges of implementation into ambulatory care settings. These include 
fewer financial resources, greater fragmentation, and a workforce less familiar with 
pharmacogenomics than those described in these numerous networks herein.33,34  The Centers for 
Disease Control and Prevention (CDC) Office of Public Health Genomics has weighed in, stating 
we must understand “what factors contribute to the success or failure of a genomic application 
within a particular setting” (blogs.cdc.gov/genomics/2017/11/27/if-you-build-it/).35 There will 
always be variability in any broadly defined setting, such as tertiary academic or primary care, 
but the differences between will typically exceed those within.  
Given the breadth of diversity in the delivery of health care, approaching implementation 
of pharmacogenomics in new settings deserves the same level of scientific rigor that allowed it to 
progress to its current point. The growing field of implementation science may offer this rigor 
through its theories, methodologies, and frameworks.36 The need for implementation science was 
born out of issues in both time it took clinical evidence-based practices to reach usage and the 
total proportion that ever did, average of 17 years and 50%, respectively.37 Though its theories 
and constructs have applications in other industries such as technology or transportation, the 
original conceptualization for implementation science was health care.37 A commonly used 
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definition of the science is “the scientific study of methods to promote the systematic uptake of 
research findings and other evidence-based practices into routine practice, and, hence, to 
improve the quality and effectiveness of health services”.37 Implementation science is most 
commonly organized into five foundational concepts: 1) diffusion, 2) dissemination, 3) 
implementation, 4) adoption, and 5) sustainability.38 These concepts are to be viewed as part of 
feedback loop with the achievement of sustainability leading to the ability to diffuse new ideas, 
behaviors, and practices. Effective implementation is at the center of these five concepts as each 
should be considered during the design process of bringing an evidence-based intervention or 
practice into usage.36 As a relatively new science, it is not without its own set of challenges that 
must be overcome. Some of these include: a lack of common language (a continuing issue in 
genomics and pharmacogenomics), short-termism, and a lack of embedded evaluation plans. 
These last two have been highlighted for their application to this dissertation. Short-termism can 
parallel with the last ‘foundation concept’ of sustainability, and a ‘lack of embedded evaluation 
plans’ helps illuminate that not only are intervention outcomes important, but also the need to 
develop implementation-specific outcome measurements.  
The foundational concept of sustainability has received increasing attention as one of the 
most important, yet more misunderstood concepts of implementation science.39 In fact, recent 
work attempted to unify the discussion on sustainability through a paper on the development of a 
comprehensive definition.40 Although commendable, in the spirit of Proctor et al. sustainability 
is likely more complex than only one definition.39 How one defines sustainability in an 
individual study should be explicitly rationalized or come from a previous publication.39 The 
contradiction between this and the just mentioned ‘lack of common language’ exhibit the 
complexities implementation science researchers are facing. However, this Proctor et al. paper 
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represents a seminal work to identify the most important issues for research in sustainability. A 
concept-mapping approach was used that are encompassed in three overarching domains: 1) an 
agenda unified through answering the high priority research questions on sustainability 2) 
methodology advancement for sustainability research 3) and advance infrastructure to support 
this research. These domains are characterized by 91 unique statements within 11 unique 
conceptual clusters within five larger clusters.39   
Methodological advancement of sustainability will require the application of individual 
frameworks in study design and execution. A systematic review of the sustainability landscape 
revealed 62 publications where a unique sustainability approach was used. These include 32 
frameworks, 16 models, 8 tools, 4 strategies, 1 checklist, and 1 process.41 The obvious 
observation is that the selection of a framework or model can overload the researcher’s choice-
set. However, taking a high-level view of multiple disciplines can train the eye to identify where 
there are overlays in the needs of the discipline being applied to the sustainability framework, as 
well as ways in which the framework itself can address issues within its own parental discipline 
of implementation science.  
The Dynamic Sustainability Framework (DSF) is a framework built around seven major 
tenets the authors recommend for explicit testing (Table 1) and a visual model (recreated in 
Figure 1).42 The DSF was designed based on previous literature that put forth an alternative 
conceptualization of sustainability as a cyclical “change process” that provides adaptability in 
pre-implementation stages such as planning and organizational support rather than an outcome or 
metric of successful implementaiton.43,44 Sustainability is further operationally defined in three 
more specific constructs: maintenance, institutionalization, and (infrastructure) capacity 
building.38 The sustainability planning model operationalizes capacity building as both physical 
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and human infrastructures: structures and linkages, champions and leadership, resources, policies 
and procedures, and expertise.43,45 The operationalization of capacity building as a human 
infrastructure is an important development for this dissertation.  
Table 1. Tenets of the Dynamic Sustainability Framework 
1 • Interventions need not (and should not) be optimized prior to implementation 
2 • Interventions can be continually improved, specific to each setting 
3 • Ongoing feedback is essential and should be measured over time 
4 • More diverse/complex populations does not mean an inevitable loss in benefit 
5 • Strong ‘fit’ is essential, but it will likely change over time 
6 • Organizational learning should be at the core 
7 • Stakeholder involvement throughout all processes 
                              
Figure 1. Recreation of the Dynamic Sustainability Framework  
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Highlighted throughout the DSF is an emphasis on ongoing adaption and evaluation of an 
intervention with the goal of continuous improvement to determine its optimal ‘fit’ across 
various ‘practice settings’. Designing implementations with a DSF-type mindset may make 
headways in addressing the previously mentioned, ‘lack of embedded evaluation plans’ 
challenge for implementation science. As part of this, valid and reliable outcome measurements 
for implementation research are being developed. A systematic review found 104 measurement 
instruments in a core set of outcomes previously identified: acceptability, adoption, 
appropriateness, cost, feasibility, fidelity, penetration, and sustainability.46,47 Approximately two-
thirds measured acceptability and adoption, with all others having less than 10 measurements. 
Psychometric strength and quality were also highlighted as being underdeveloped. In response, a 
follow-up study by some of the authors developed, and psychometrically assessed, three new 
measures with promising psychometric properties: Acceptability of Intervention Measure (AIM), 
Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM).48 
These measures are utilized in the manuscript and described in Section III. 
Calls to begin cultivating a formal relationship between implementation science and 
precision medicine, as well as the learning health system, have been made in the past several 
years.49 The National Academies of Sciences, Engineering, and Medicine recently held a 
workshop entitled “Applying an Implementation Science Approach to Genomic Medicine”. The 
report emphasizes a focus on methods to encourage wider participation from minority and 
disadvantaged populations, evidence building and clinical research done in parallel (aspects of a 
learning health care system), and a focus on genomic applications to improving population 
health.50 The lack of implementation science frameworks in the National Institutes of Health’s 
grant portfolio for genomic medicine may be a contributor to these calls. From 2012 to 2016, 
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only 1.75% of genomic related grants included the formal use of an implementation science 
framework.51 This equates to a total of four grants, all of which used the same framework, 
Rogers’ Diffusion of Innovation.51 This seminal work by Everett Rogers provided the field of 
implementation science with several key components of innovation diffusion including 
perceptions of the innovation itself such as compatibility, the degree of innovativeness in the 
adopter, the environment of the adopter and the systems in place in the environment, and lastly, 
the actual process of adoption.52 Implementation science has built on the breadth of Rogers’ 
ideas and created immense depth, as evidenced by the DSF, into each of these components, as 
well as creating new layers of breadth with frameworks such as the Consolidated Framework for 
Implementation Research (CFIR) which will be discussed below.53 Rogers’ original work in 
agriculture has been extrapolated to countless scientific disciplines and thus, this work, and 
others utilizing the discipline of implementation science, should be read not only as contributing 
to their specific fields but as important additions to the general pursuit of evidence-based 
scientific practice. 
In addition to the lack of implementation science grants, the CDC’s Public Health 
Genomics Knowledge Base was used to identify published literature where implementation 
science has been applied to genomics medicine. Although the findings showed a total of 283 
articles published in 2014, the inclusion criteria did not specify that a formal implementation 
science approach be taken, rather that the studies “contributed to our understanding of the 
implementation of genetic/-omic testing…”. In fact, what was discovered was that very few 
studies actually incorporated a theoretical framework from implementation science, any measure 
of sustainability, or capacity building (a key component of sustainability).38,54  
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Two working groups from IGNITE, Common Measures and Sustainability, recently put 
the field of genomics in more rigorous alignment with implementation science, and its 
foundational concept of sustainability.53,55 The Common Measures group utilized the CFIR, one 
of the most robust widely used frameworks of implementation science.53 This framework is 
composed of five domains containing 39 constructs or sub-constructs and was built from a large 
scale evaluation of available implementation science theories, with an end goal of producing a 
pragmatic way to improve this science. The CFIR now has its own dedicated website 
(cfirguide.org) which provides both quantitative and qualitative data collection tools, analysis 
methods, and interpretation resources.  
Though the IGNITE work did not specify pharmacogenomics, many of the takeaways are 
logically applicable to it. The working group evaluated the 39 constructs of the CFIR for their 
contribution and importance to genomic medicine.45 The 10 highest-ranking constructs were 
included in the final list, with the intention to develop data collection tools for the network. Table 
2 provides a list of these constructs. The construct “patient characteristics” was included as high-
priority although it is a non-CFIR construct. The authors found that the CFIR lacked “well-
defined representation of patient-related domains”. While patients do represent a critical aspect 
of implementing a new intervention effectively, they believe that this impact is less influential 
than the clinicians and institutional leadership when it comes to initial implementation 
successes.45  
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Table 2. High-priority CFIR and *non-CFIR constructs identified by IGNITE CMG             
Knowledge 
and beliefs 
about the 
intervention 
Self-efficacy Implementation 
climate 
Readiness for 
implementation 
Relative 
Advantage 
Cost Engaging Executing Reflecting & 
Evaluating 
Patient 
characteristics* 
 
An effort was made to identify existing measurement tools for these 10 constructs, and to 
move forward with the development of novel ones where no existing measures had been 
developed.  While many of the ‘patient characteristics’ sub-constructs had reliable and valid 
measurement tools already in place, most of the high-priority constructs from CFIR did not. This 
led to an initiative to create these measures, including the pre-implementation provider survey 
among others freely available in the IGNITE Spark Toolbox (ignite-genomics.org/spark-
toolbox/researchers/). The CFIR has also been used in other genomic-focused papers. For 
example, Lynch Syndrome screening is a condition that can raise the lifetime risk of developing 
colorectal cancer by as much as 4%, but has faced heterogeneous barriers to implementation that 
the authors believed implementation science, and the CFIR could address.56,57 Though not an 
explicit test of the constructs, the paper focused on Lynch Syndrome matched relevant domains 
of the CFIR with potential applications for Lynch Syndrome, somewhat similar to the IGNITE 
work with the framework. The CFIR, and in particular the Process domain, guided the 
development and data collection of the study described in Section II of this dissertation. The 
Process domain of the CFIR contains four constructs (Planning, Engaging, Executing, Reflecting 
& Evaluating). The Engaging constructs is made of up of six sub-constructs (formally appointed 
implementation leaders, opinion leaders, champions, key stakeholders, innovation participants, 
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and external change agents). In their original work, the authors of the CFIR describe the 
constructs of the Process domain as the “essential activities of implementation processes that are 
common across organizational change.”53  
In a complementary work, the IGNITE Sustainability Working Group identified 28 
constructs most important in sustainability of genomic medicine.55 Again, these results apply to 
genomics as a whole, but can be logically extrapolated to pharmacogenomics. These 28 
constructs were arrived at by crossing sever key drivers of sustainability elicited from an open-
ended survey with principal investigators and working group chairs within IGNITE. The second 
survey collected a ranking of these drivers with applications across patient, provider, payer, and 
government stakeholders. Table 3 shows the key drivers.  
Table 3. Key drivers of genomic sustainability        
Key Drivers 
Infrastructure (EHR, 
CDS, lab, manufacturers, 
community) 
Economic 
measures 
Clinical 
evidence/effectiveness 
Regulatory/legal Research/development 
Workforce 
impact 
Education 
 
The top results, those identified as the top five most important of the second survey were 
(1) expanded genomic education, (2) availability of clinical decision support (CDS) tools, (3) 
formal recognition of economic data guiding reimbursement decisions (4) the impact of 
integrating genomic information into workflow, and (5) need for reimbursement decisions and 
prior authorization regimes. As one can see, these constructs can be easily split into two groups: 
those that directly affect the provider in the context of delivering genomic medicine and those 
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that affect reimbursement and coverage policies to pay for genomic testing. The former will be 
the focus herein.  
A recent review of the pharmacogenomic landscape led by many leaders in the field 
includes brief reflections on things learned, recommendations on improvements, and future 
directions.58  Included in these reflections are several of the same things that IGNITE found to be 
important to sustainability: workforce education, clinical tools for genomic implementation of 
pharmacogenomic variants, availability of pharmacogenomic testing (often driven by 
reimbursement), and others. Some of the most pressing issues noted by physicians specifically 
are the development of effective clinical decision support tools and educational training 
mechanisms.59 
One important thing discussed in this review that appears to have been missed by the 
IGNITE Sustainability group was the importance of stakeholder alignment and transdisciplinary 
teams (interdisciplinary or multidisciplinary could be used). They list the full gamut of potential 
partners, from other clinicians to patients to payers to engineers etc. Set forth by the TPP, the 
implementation of pharmacogenomics was intended to be a multidisciplinary effort, leveraging 
the expertise of various clinicians and researchers. Clinical collaboration in pharmacogenomics 
involving the pharmacist has been a particularly important component of its delivery.60-62 Several 
pharmacogenomic implementation sites have been initiated and driven by pharmacists and 
pharmacy departments. These include St. Jude Children’s Research Hospital, a co-principal 
investigator of the CPIC grant, and the University of Florida, which has led the efforts of the 
IGNITE Pharmacogenomics working group.60,61,63 
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Appropriate education and thus the ability to confidently apply pharmacogenomics to 
clinical care appear to be lacking among both types of providers.34,64,65 Those physicians that 
have been part of one or more of the pharmacogenomic initiatives described throughout here 
have reported more favorable views toward genetic testing applications and a better sense of 
preparedness.59  These results would likely be similar when comparing pharmacists involved in a 
pharmacogenomic initiative or not. The collaboration of pharmacists may well provide a set of 
complementary skills, including advanced training in the pharmacokinetics and 
pharmacodynamics that apply so importantly to pharmacogenomics.66  Formal mechanisms such 
as collaborative practice agreements (CPAs) and collaborative drug therapy management 
(CDTM) programs may be important to creating the appropriate infrastructure to enable this. 
CPAs and CDTMs expand the role of the pharmacists’ involvement with the patient through a 
team-based approach, and working in a defined protocol that can include assessments, 
counseling, ordering diagnostics, and managing the patient’s drug regime.67 Several studies have 
illuminated the benefits of pharmacist involvement in the patient care team and the positive 
outcomes across the spectrum, from clinical to humanistic.68-70 These successes in 
interdisciplinary environments and a well-primed skill set to engage with pharmacogenomics 
make this a logical investigation. 
Given that most health care delivered in the US is not done at an academic institution, 
there must be greater consideration of how pharmacogenomics can be successfully implemented 
into ambulatory care, thus sustaining it beyond the externally-funded academic center, and 
achieving those goals that the National Academies stressed implementation science and 
genomics should address. Although sustainability may be difficult to define, the definition used 
in the DSF, taken from Rabin et al., fits this current issue quite nicely: “to what extent an 
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evidence-based intervention can deliver its intended benefits over an extended period of time 
after external support from the donor agency is terminated”.38 
This work is organized in three sections all relevant to the above discussion. Framed by 
implementation science and the foundational concept of sustainability this dissertation sought to 
achieve three goals: 
1. To provide a characterization of the nature and extent of the peer-reviewed 
literature on the prospective and retrospective experiences with and actions of 
health care providers when using pharmacogenomic information through a 
scoping review. This work is framed around a core research question developed 
from several tenets of the DSF and constructs related to the sustainability of 
genomic medicine.  
2. Elicit the experiences of early adopter leadership in pharmacogenomic 
implementation through the questions posed by the CFIR Process domain. The 
majority of the constructs in the Process domain were identified as high-priority 
constructs for genomic medicine. Qualitative in-depths interviews served as the 
data collection methodology.  
3. To assess the perceived acceptability, appropriateness, and feasibility of 
delivering pharmacogenomic in primary care through scenarios of a formal 
physician-pharmacist collaborative practice environment. A factorial vignette 
analysis manipulated scenarios of collaboration and other variables important in 
the considerations of pharmacogenomic testing.  
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SECTION I. 
DECISION MAKING IN CLINICAL PHARMACOGENOMICS:                          
A SCOPING REVIEW 
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1.  BACKGROUND 
Barriers to the scale up and spread of pharmacogenomics in clinical practice have been 
thoroughly discussed over the past decade.1-4 While many of these barriers have been addressed, 
numerous obstacles persist that preclude the successful application of clinical pharmacogenomics 
beyond current institutions enabled by extramural or internal financial support. These obstacles 
include an underdeveloped clinical decision support infrastructure, lack of third-party payer 
coverage policies and reimbursement, and limited clinician and patient understanding.1,5-9 
Several of these barriers were also highlighted in a recent work from the Implementing 
Genomics into Practice (IGNITE) consortium, which ranked 28 important constructs for the 
sustainability of genomic medicine.10 Interestingly, three of the top five ranked constructs (1, 2, 
and 4) focused on provider needs and included: (1) expanded genomic education, (2) making 
clinical decision support (CDS) tools available, and (3) integrating genomic information into 
workflow.  
A casual scan of the literature reveals numerous descriptive or cross-sectional studies 
aimed at assessing the attitudes of providers toward pharmacogenomics. The descriptive papers 
seen throughout the literature come, in large part, from the implementation initiatives established 
at numerous academic hospitals across the US and abroad.11-14 Cross-sectional survey work 
largely focuses on the attitudes, awareness, and concerns of clinical respondents regarding 
pharmacogenomics. Furthermore, the literature finds that most have positive views of 
pharmacogenomics, yet feel unprepared to deliver it practice.6,15-18 These studies highlight the 
need for further education and intervention. While these papers are helpful in understanding the 
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nuances and considerations necessary to establish a pharmacogenomic program, they typically 
do not include a measurement or assessment of the intervention’s impact on those delivering it to 
patients. However, the fact that this barrier continues to persist indicates that there is likely a 
dearth of studies that actively measure provider response to using pharmacogenomics in clinical 
workflow, or assessing experiences following actual clinical usage of such pharmacogenomic 
information.  
Real-world assessments and intervention-based studies are crucial as they provide 
actionable insights to others either currently using or planning to use clinical pharmacogenomics 
for patient care. The Dynamic Sustainability Framework (DSF) emphasizes the idea of ongoing 
evaluation and adaptability of an intervention to achieve the goal of continuous improvement.19 
Two tenets of the DSF, the continual improvement of the intervention and a focus on collecting 
ongoing feedback about the intervention fold together the importance of measuring actual use of 
an intervention and its impact on the sustainability of the intervention long-term.19 Learnings and 
processes from the continuous quality improvement (CQI) literature combined with the rigor of 
more evaluative research methodologies can lead to a better understanding of what changes are 
effective in improving clinical delivery of pharmacogenomics while developing generalizable 
methodologies for application in other settings.  
With these considerations, our review is focused on answering the following research 
question: How have the prospective or retrospective experiences and actions of prescribers, 
pharmacists, or genetic counselors been measured when using pharmacogenomic information in 
either real-world practice or a hypothetical research setting? The current objective of this review 
is to provide a characterization of the nature and extent of peer-reviewed literature that is 
applicable to the stated question. A scoping review was the appropriate review methodology as it 
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aims to assess the extent, range, and nature of evidence to summarize heterogeneous methods or 
disciplines, without pursuing a quality assessment of the literature.20 
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2.  METHODS 
To increase the methodological transparency and uptake of these findings, the recent 
checklist extension by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) published for scoping reviews (PRISMA-ScR) was used throughout this study.21  
Protocol and Registration 
A registered protocol was not developed prior to beginning the search of the literature. 
However, the PROSPERO international prospective register of systematic reviews was searched 
and there was no registered protocol when this project began in December of 2018 that exhibited 
similarities in research objective or design.  
Eligibility criteria 
Detailed inclusion and exclusion criteria were developed prior to the first screening of the 
search results. To be included in the review, papers must include an outcome that measures the 
experiences of or action by a prescriber (physician or advanced-practice provider), pharmacist, or 
genetic counselor when engaged in an actual or hypothetical scenario involving 
pharmacogenomic testing. Published papers that were descriptive of an implementation project 
and included provider elements yet do not include formal data collection methods were excluded. 
Table 1 fully describes the inclusion and exclusion criteria. 
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Table 1. Inclusion/exclusion criteria 
Inclusion 
criteria 
Peer-reviewed literature in pharmacogenomics that evaluates the clinical 
professional’s experience or action taken when using pharmacogenomic 
information for clinical decision making 
At least 50% of the data must come from responses or decisions made by 
physicians (MD/DO), pharmacists (RPh/PharmD), or genetic counselors (CGC).  
Exclusion 
criteria 
Studies that do not clearly state respondents have used or are using 
pharmacogenomic information. This includes any study that is descriptive, 
anecdotal, or opinion in nature. 
Studies published that only include as respondents: patients, advanced practice 
non-physician providers (nurse practitioners/physician assistants), health 
profession students, or nurses. 
Studies not primarily focused on pharmacogenomics  
Studies published before the year 2000 
Studies published in a language other than English 
 
Information sources and search 
 In December of 2018, potentially relevant papers were searched in the both the 
MEDLINE® and Embase® bibliographic databases. MEDLINE® uses the MeSH® (Medical 
Subject Headings), Embase® uses Emtree®. Search strategies were developed by the lead author 
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and refined through discussion with other authors. Search results were exported into Microsoft 
Excel® and duplicates removed. Microsoft Excel® was used to parse out MEDLINE® studies that 
were duplicated and those that were unique from the Embase® search.  
A total of 537 studies were pulled from MEDLINE®. The search of Embase® produced 
201 studies unique to the Embase® library, and 241 unique studies that were not included in the 
results of the MEDLINE® search. The Embase® library searches MEDLINE® in addition to its 
own database. Appendix 1 provides the full search string for each database.  
Selection of sources of evidence 
Two authors (NK and TD) independently and iteratively reviewed titles and abstracts, 
then full papers, making decisions to include or exclude at each stage. At the completion of each 
stage the selecting authors discussed their assessments and came to consensus on the studies to 
be included. Prior to beginning the selections, a screening form was developed and agreed upon 
by the authors.  
Data charting and data items 
 The data charting process used the STROBE (Strengthening the Reporting of 
Observational Studies in Epidemiology) checklist to determine which variables to extract from 
the included studies. A data-charting form was developed by the lead author and shared with a 
co-author (TD). Each author (NK and TD) took half of the included studies and independently 
charted the data using this form.  
In line with the PRISMA-ScR checklist, items 9, 11, and 12 of STROBE will be excluded 
from the data charting process. These items correspond to sections usually absent from scoping 
reviews and did not add to answering the stated research questions. Final variables included from 
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the data abstraction were author and publication year, study location, research aims, study design 
and methods, population and setting, outcome(s) of interest, and major findings. Table 2 is the 
subsequent result of this extraction.  
Synthesis of results 
Lastly, two authors (NK and MR) performed an inductive content analysis of the study 
design and study methods, as well as the major findings variables from each included article to 
structure the scoping review findings. In line with the language of the research question, the 
organization of the findings was determined according to the methodology driving the study. The 
goal of this analysis was to come to consensus on the number of major methodological groupings 
and the nature of the methods therein.    
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3.  RESULTS 
Figure 1 below provides an overview of the number of studies screened, determined 
eligible (with reasons for exclusion at each stage), and then included in the review findings. 
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- Descriptive, review, or 
opinion         (n = 553) 
- Not pharmacogenomics (n = 
153) 
- Not a physician, pharmacist, 
or genetic counselor majority 
(n = 67) 
- Language other than English           
(n = 21) 
- Published before 2000 (n = 8) 
- Other (n = 85) 
 
Full-text articles excluded, with 
primary reason (n = 64) 
 
- No actual or hypothetical 
intervention with or use of 
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(n = 44) 
- Descriptive, review, or 
opinion   (n = 15) 
- Not a physician, pharmacist, 
or genetic counselor majority 
(n = 5) 
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Studies included in extraction 
(n = 25) 
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram 
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Characteristics of sources of evidence 
A total of 25 studies underwent complete data extraction. Most studies (76.0%) were 
from North America.22-38 Two studies (8.0%) were conducted in both US and international 
settings,39,40 and the remaining were strictly conducted in strictly international settings (24.0%). 
All studies except for two came from the US and Europe.  
 Most of this research was quantitative in nature (80.0%).22,24,25,28-33,35,39-44 Only three 
studies were strictly qualitative in nature27,36,45 and two used a mixed-methods approach.23,26 
Study designs ranged from cross-sectional surveys and in-depth interviews to hypothetical 
clinical case scenarios and timed information-seeking exercises with subjects. One study took a 
quasi-experimental approach.25 As outlined in the inclusion criteria, the majority of study 
participants were physicians, pharmacists, or genetic counselors. Among the 25 studies, almost 
all (96.0%) were categorized as majority physician23,25-27,29,31-33,35,36,39-45 while only one study 
was solely pharmacist.28  
In a somewhat blended approach, the primary outcome for four physician respondent 
studies (16.0%) was adherence to therapeutic recommendations from either a pharmacist or 
pharmacist-led surveillance service.22,24,30,34 Three additional studies tracked the therapeutic 
action of a prescriber based on CDS support alerts or another return of results methods.37,38,46 
None of the 25 studies included in the scoping review focused on genetic counselors.  
 
 
 
37 
 
Table 2. General characteristics of studies included in the review (n = 25) 
Characteristics n % 
Region of origin*   
   North America 20 80.0 
   Europe 6 24.0 
   Oceania 1 4.0 
Years published   
   2015 – 2018 17 68.0 
   2010 – 2014 7 28.0 
   2005 – 2009 1 4.0 
   2000 - 2004 0 0.0 
General methodology   
   Quantitative 17 80.0 
   Qualitative 3 12.0 
   Mixed Methods 2 8.0 
Study design   
   Hypothetical clinical case scenarios 9 40.0 
   Real-world studies on prescribing/testing decisions 7 28.0 
   Cross-sectional quantitative surveys 5 16.0 
   Cross-sectional qualitative interviews 3 12.0 
   Quasi-experimental 1 4.0 
* Total equals more than 100% due to multi-country studies included   
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Results of individual sources of evidence 
 Table 3 provides an evaluation of each study across all included variables for data 
extraction. The qualitative content analysis of the study design and methods section revealed five 
major methodological approaches: hypothetical clinical case scenarios, real-world studies 
evaluating prescriber response to recommendations or alerts, cross-sectional quantitative 
surveys, cross-sectional qualitative surveys/interviews, and a quasi-experimental real-world 
study. In the following sections, each methodological approach will be defined with appropriate 
sub-sections and aims identified, and a brief mention of major study findings will be provided. 
Table 3. Peer-reviewed articles included in the scoping review 
Author and 
Publication 
Year 
Study 
Location 
Research Aims 
Study Design and 
Methods 
Population and 
Setting 
Outcome(s) of 
Interest 
Major Findings 
Bain et al. 
2018 
United 
States 
To determine the 
feasibility of 
implementing a 
pharmacist led 
PGx service for 
the Program of 
All-Inclusive 
Care for the 
Elderly (PACE). 
Prospective 
evaluation of the 
implementation 
processes in PACE. 
This included 
reviewing policies 
and procedures, 
observations 
documented by the 
pharmacists, 
prevalence of genetic 
variants, and drug-
gene interactions, 
descriptive 
categorization of the 
types of pharmacist 
recommendations, 
and prescriber 
acceptances of these 
recommendations. 
The practice 
setting in which 
this evaluation 
was made was a 
centralized 
pharmacy in 
New Jersey that 
services 15-
20% of PACE 
participants in 
21 states. PGx 
consultations 
were led by two 
senior 
pharmacists and 
a pharmacy 
resident. 
Included 
prescribers 
were those who 
selected testing 
based on their 
medical 
decision. 
Rates of 
prescribers' 
acceptances of 
the PGx 
consultation 
recommendation
s, when feasible. 
Eighty-nine percent 
of pharmacist 
recommendations 
were accepted by 
the referring 
prescriber. 100% of 
recommendations 
were accepted in the 
categories: continue 
drug (no change), 
consider drug dose 
adjustment, and 
consider drug 
regimen change. 
38.5% of 
recommendations 
were accepted for 
the category 
implement drug 
dose adjustment or 
drug regimen 
change. 
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Blagec et al., 
2016 
Austria 
and 
United 
States 
To evaluate the 
perception and 
usability of a 
web- and mobile-
enabled CDS 
system (the 
Medication 
Safety Code 
(MSC)) for 
pharmacogenetic
s-guided drug 
therapy among 
physicians and 
pharmacists. 
Survey B was a 
quantitative 
assessment of 
physician and 
pharmacist attitudes 
toward the MCS 
system based on two 
hypothetical use 
cases. Twenty-five 
follow-up questions, 
including a 16 item 
Likert scale, were 
used to measure 
usability, 
trustworthiness, 
usefulness, and 
workflow integration. 
Survey B 
included a final 
sample of 39 
physicians and 
pharmacists, 
with an 
overwhelming 
majority from 
Austria or 
Germany 
(~90%). 
Scores on the 
usability, 
trustworthiness, 
usefulness, and 
workflow 
integration 
subscales and total 
scale score. 
Out of a possible 
max score of 16, 
usability scored 
an average of 
10.6, 
trustworthiness a 
10.5, usefulness a 
11.4, and 
workflow 
integration a 9.9. 
This equates to a 
total scale score 
of 42.3 out of 
64.There was no 
statistically 
significant 
difference 
between 
physicians (43.7) 
and pharmacists 
(38.8), or 
between 
respondents 
aware or unaware 
of genome 
guided 
prescribing and 
clinical decision 
support systems.  
Devine et al., 
2014 
United 
States 
To evaluate an 
early prototype, 
commercial 
CPOE 
system with 
PGx-CDS alerts 
in a simulated 
environment, to 
identify potential 
improvements to 
the system user 
interface, and to 
understand the 
contexts under 
which PGx 
knowledge 
embedded 
The study used a 
convergent, parallel, 
mixed methods 
design. Physicians 
were given five 
hypothetical clinical 
case scenarios 
featuring a 
pharmacogenomic 
alert message 
triggered by a 
medication order. 
Audio-video 
recordings were 
coded according to 
positive and negative 
evaluation heuristics.  
Seven 
cardiology 
fellows and 
three oncology 
fellows at the 
University of 
Washington. 
Time to completion 
of prescribing task. 
Themes and 
improvements 
identified using the 
heuristic evaluation 
technique.  
Each physician 
spent between 
3.6 to 4.9 
minutes per 
prescribing task. 
Nine themes and 
corresponding 
improvements 
emerged from the 
heuristic 
evaluation. Five 
included 
improvement 
suggestions for 
the CPOE user 
interface, two 
suggested 
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in an electronic 
health record is 
useful to 
prescribers. 
including PGx 
information 
through alerts, 
and three 
emphasized the 
need for relevant 
guidelines and 
dosing 
recommendations
. 
Dunbar et al., 
2012 
New 
Zealand 
Feedback from 
clinicians on 
their experiences 
ordering a 
AmpliChip® 
CYP450 test kit, 
receiving results, 
utilization of the 
results, and 
perceived 
advantages and 
disadvantage for 
commencing 
treatment with 
risperidone.   
Once an appropriate 
patient was 
identified, the 
clinician was directed 
to prescribe 'as 
usual', then complete 
an order form for the 
patient to get the 
testing done. Results 
were fed back to the 
clinicians directly. 
Ordering clinicians 
were contacted to 
complete a 
qualitative interview.  
Forty-two 
clinicians 
ordered the test 
and a total of 33 
were 
interviewed by 
a member of the 
research team. 
Clinicians 
worked across 
three District 
Health Boards 
within New 
Zealand. 
Key ways in which 
the test results were 
used and the 
perceived 
advantages and 
disadvantages of 
using the test.  
Test results 
utilization: 
confirm a clinical 
decision, provide 
reassurance, 
provide 
additional 
information on 
patient response, 
influence the 
dose of 
risperidone, and 
doctor-patient. 
Several reasons 
for not using 
results were 
delays in 
receiving results, 
inappropriate 
setting (acute 
unit with 
requirement to 
treat 
immediately), 
information 
deemed 
unnecessary, and 
others Dose 
determination, 
reduction of 
adverse effects, 
and application 
outside mental 
health were noted 
advantages. 
Disadvantages 
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included results 
being used at the 
expense of 
clinical 
judgement, cost, 
and practicalities 
of the testing 
process and 
results reception.  
Ferreri et al. 
2014 
United 
States 
To determine the 
feasibility of 
implementing a 
PGx service in a 
community 
pharmacy. 
Prospective 
evaluation of the 
program's feasibility 
following a 
retrospective data 
abstraction of 
prescription fills for 
clopidogrel between 
the dates of May 1, 
2011 and October 26, 
2011.  
A single 
pharmacy 
within a 
regional chain 
known for 
providing 
clinical 
services.  
Rate of prescriber 
acceptance to a 
Clinical Pharmacist 
Practitioner (CPP) 
recommendation 
across five different 
genotypes (*1/*1, 
*1/*2, *1/17, 
*17/*17, and 
*2/*17). The 
number of patients 
with each were 9, 2, 
4, 1, and 2, 
respectively. 
The majority of 
CPP 
recommendations 
were approved 
by the prescriber. 
There was 100% 
approval across 
genotypes *1/*1 
(EM), *17/*17 
(UM), and 
*2/*17 (IM). 
Genotype *1/*2 
(IM) was 
approved 50% of 
the time, the 
other 50%  were 
started on aspirin 
EC 325 mg daily. 
For genotype 
*1/*17 (UM), 
75% were 
approved. 
Clopidogrel was 
discontinued in 
the other patient.  
 
Haga et al., 
2017 
United 
States 
To investigate 
provider 
utilization of 
pharmacist 
support in the 
delivery of PGx 
testing in a 
primary care 
setting. 
Two primary care 
practices were 
assessed, one with a 
pharmacist in the 
clinic and one with 
available pharmacist 
on-call support. 
Physicians answered 
a survey assessing 
attitude, knowledge, 
and experience with 
PGx testing before 
Twelve primary 
care providers 
from two 
internal 
medicine clinics 
within the Duke 
University 
Health System 
Results from the 
follow-up survey to 
assess perceptions 
and comfort using 
PGx. Patient charts 
provided the 
number of PGx 
tests ordered in 
each arm of the 
trial. Variables of 
interest recorded by 
the pharmacist 
Five of nine 
providers 
strongly or 
somewhat agreed 
that felt more 
informed about 
PGx testing after 
the trial. Six felt 
more 
comfortable 
discussing PGx 
with patients 
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and after attending a 
PGx seminar. 
included the 
number of times a 
pharmacist was 
consulted (pre-test 
or post-test), and 
how the results 
were applied to 
treatment. 
after. Sixty-three 
total tests were 
ordered, 48 being 
ordered from the 
pharmacist-in-
house arm 
(p<0.00001). 
Physicians 
consulted 
pharmacists in 13 
of the 15 cases in 
the in-house 
pharmacist group 
compared to 7.5 
out of 15 in the 
on-call group. 
Heale et al., 
2017 
United 
States 
To investigate 
physicians' 
information 
needs and 
information-
seeking behavior 
when exposed to 
pharmacogenomi
cs case vignettes. 
Mixed methods 
approach consisting 
of a pre-study 
questionnaire of 
attitudes and 
knowledge regarding 
pharmacogenomics, 
observation of 
information-seeking 
in three case 
vignettes, and a post-
study questionnaire 
and interview. 
A purposive 
sample of six 
physicians, five 
male and one 
female. Three 
were between 
30 and 39 years 
old, two 40 to 
49, and one 60 
to 69.  
For information-
seeking behavior in 
the vignettes: time 
spent by physician 
on information-
seeking, time 
between 
navigational actions 
and number, 
number of searches 
entered. Categories 
of the information 
needs from post-
study assessment. 
Average number 
of minutes spent 
in information-
seeking session 
was 8:22 (2:41 to 
15:08), time 
between 
navigation was 
0:53 (0:03 to 
8.27), number of 
page navigation 
events per 
subject per case 
was 8 (1 to 18), 
and the number 
of searches was 
2.3 (1 to 8). 
Follow-up 
assessment 
identified six 
information 
needs categories 
from 11 themes: 
alternative 
therapies 
obviating testing, 
guidance on 
when and how to 
test, frequency 
testing is 
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indicated, 
evidence of 
importance of 
genetic testing, 
help in 
understand 
genetic effects, 
and aid in 
searching for 
information. 
Ielmini et al., 
2018 
 
Italy 
 
To identify if the 
treatment 
prescribed by the 
psychiatrist was 
consistent with 
the treatment 
suggested by the 
PGT at T0 and to 
assess if 
clinicians had 
changed the 
treatment (in 
case of 
discordance) at 
T1 (3-month 
follow-up visit) 
according to the 
results of the 
pharmacogenetic 
test (PGT) 
 
Observational study 
with a follow-up at 3 
months. At baseline 
(T0), patients 
received genetic tests 
and were given 4 
scales. At the follow-
up (T0), changes to 
treatment and 
adverse events were 
recorded.  
 
Psychiatrist 
decision 
making for 30 
bipolar type 1 
and 2 patients 
who received 
PGT 
Neurofarmagen 
at 2 psychiatric 
institutes  
 
Patients' overall 
assessment and 
clinical evolution 
was measured using 
the Clinical Global 
Impression. The 
Hamilton 
Depression Rating 
Scale assessed 
anxiety-depressive 
symptoms. The 
Young Mania 
Rating Scale 
assessed manic 
symptoms. The 
Dosage Record and 
Treatment 
Emergent Symptom 
Scale assessed onset 
of side effects 
relating to ongoing 
pharmacological 
therapy 
At baseline, 13% 
of patients 
received optimal 
therapy. At 
follow-up, 40% 
of patients 
changed to a 
therapy 
consistent with 
the results of the 
Nerofarmagen 
test and 32% 
maintained a 
therapy 
disagreeing with 
the test. A 
significant 
within-group 
reduction in 
adverse events 
was observed in 
patients who 
received therapy 
modification  
 
Laerum et al., 
2013 
Norway Develop a 
prototype for 
automated 
interpretation of 
genetic tests and 
evaluate hospital 
physicians’ 
reactions to it in 
a specific use 
case. 
Algorithm applied to 
the interpretation of 
CYP3A5 and its 
impact on the 
metabolism of  
immunosuppressive 
drug tacrolimus. 
Respondents used the 
"think aloud" 
technique to vocalize 
thoughts and 
Nine 
experienced and 
less-
experienced 
physicians, five 
of which 
completed 
specialties after 
qualifying as a 
Medical Doctor. 
One physician 
Median time to 
resolve the two 
scenarios presented 
and the speech and 
actions recorded 
while using the 
application. 
Reactions to the 
application after 
completing the 
scenario. 
Scenario 1 took 
on average 164 
(110 to 339) 
seconds to 
complete. Most 
of the physicians 
were observed to 
not immediately 
grasp the concept 
of "interpreted 
report" versus 
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considerations during 
the application. 
Scenarios involved 
viewing and 
resolving two patient 
scenarios with regard 
to tacrolimus 
treatment. Physician 
speech and actions 
on the screen were 
recorded and they 
were asked to 
identify the correct 
dosing for the given 
patient. 
had a PhD in 
molecular 
genetics. 
original genetic 
data. Scenario 2 
took less than 
half the time to 
resolve on 
average than 
scenario 1. 
Physician 
attitude to the 
application was 
generally very 
positive. Some 
details were 
reported too 
extensive, 
unclear, or 
difficult to 
understand.  
Lemke et al., 
2017 
United 
States 
 To explore 
primary care 
physicians’ 
views of the 
utility and 
delivery of direct 
access to PGx  
testing in a 
community 
health system. 
Study participants 
received 
complimentary PGx 
testing kits for 
themselves and for 
their patients. 30-
minute qualitative 
semi-structured 
interviews were 
conducted to identify 
viewpoints related to 
primary care 
physician PGx 
clinical decision-
making. 
Fifteen primary 
care physicians 
in the 
NorthShore 
University 
Health System, 
a four-hospital 
community 
health system.  
Broad themes and 
associated sub-
themes from the 
qualitative analysis 
were the primary 
outcome. 
The three broad 
themes were 
perceived value 
and utility of 
PGx testing, 
implementation 
challenges, and 
provider and 
patient needs. 
The first theme 
here included 
two sub-themes: 
how test findings 
can be used to 
guide primary 
care decision-
making, and how 
information from 
testing can lead 
to specific 
positive 
outcomes for 
patients. 
Manzi et al, 
2017 
United 
States 
To describe the 
development and 
implementation 
of a 
comprehensive 
A retrospective 
evaluation of the first 
two years of 
operation (August 
2012 to August 
A total of 160 
alerts across 31 
patients 
interfaced with 
69 unique 
Percentage of 
prescribers who 
cancelled the order 
in response to alert, 
percentage who 
23% of 
prescribers 
cancelled the 
order in response 
to the TPMT 
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clinical 
pharmacogenomi
cs service within 
a pediatric 
tertiary care 
urban teaching 
hospital 
2014) of TPMT 
single gene 
sequencing and the 
subsequent actions of 
the clinician based on 
the CDS alert 
practitioners. 
53% physician, 
22% 
pharmacists, 
18% nursing 
with physician 
co-sign, and 7% 
nurse 
practitioners   
initiated a modified 
dose after alert, and 
percentage of tests 
order prior to initial 
prescription 
alert. 71% of 
prescribers 
modified the 
dose after 
receiving the 
alert for the 
initial 
prescription. 90% 
of tests were 
ordered prior to 
the drug being 
ordered  
McMichael et 
al., 2017 
Northern 
Ireland 
To demonstrate 
how attribute 
nonattendance 
analysis can be 
used in medical 
decision making 
to assess whether 
psychiatrists 
were influenced 
in their treatment 
recommendation
s by information 
on the genotype 
of a patient, 
despite knowing 
the patient’s 
response to 
treatment. 
Psychiatrists were 
given patient's pre or 
post treatment 
symptom scores on 
the Positive and 
Negative Syndrome 
Scale (PANSS) for 
two treatments of 
schizophrenia, were 
told whether patients 
had a genotype 
linked to one of the 
treatments associated 
with a 30% increase 
in effectiveness and 
were asked to 
recommend a 
treatment. Twenty-
six vignettes assessed 
the effect of each 
attribute on 
psychiatrists' 
treatment 
recommendations. 
Sixty-seven 
practicing 
psychiatrists 
from Northern 
Ireland 
recruited during 
continuous 
professional 
development 
meetings in 
three hospitals. 
Psychiatrists 
estimated 
probability that they 
will either ignore or 
attend to 
information about 
the patient genotype 
when already 
presented their 
PANSS scores pre 
and post.  
Across the entire 
sample, there 
was an 84% 
probability that 
psychiatrists did 
not consider the 
patient genotype 
information and 
16% probability 
they did when 
already present 
with the patient’s 
response to 
treatment. 
Psychiatrists with 
less than one 
year of clinical 
experience were 
significantly 
more likely to 
incorporate 
irrelevant genetic 
information into 
patient treatment 
(46% 
probability). 
Those with more 
than 15 years had 
a 7% probability 
of incorporating 
the same 
information.  
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Moaddeb et 
al., 2015 
United 
States 
To characterize 
the experiences 
and feasibility of 
offering 
pharmacogenetic 
testing in a 
community 
pharmacy 
setting. These 
included the time 
to provide the 
testing, patient 
interest, 
perceptions of 
patients' post-test 
comprehension, 
pharmacists' 
interactions with 
prescribing 
physician, and 
changes made to 
prescription 
based on the 
results. 
Pharmacists 
completed surveys at 
two time points for 
each patient that was 
offered PGx testing. 
One for when the 
testing was offered, 
and another after 
testing was 
completed and test 
results were 
communicated. 
Testing was offered 
for CYP2C19 and/or 
SLCO1B1 
Community 
pharmacists in 
North Carolina 
across five 
community 
pharmacies.  
Length of the pre-
test counseling, the 
medium in which 
results were given 
to the patients and 
how long that took, 
the pharmacist's 
belief of how well 
the patient 
understood the 
results, and what 
percentage of result 
interpretations were 
done correctly. 
Over 80% of pre-
test counseling 
was under five 
minutes, 84% of 
results were 
communicated 
by phone, 
pharmacists 
believed 95% of 
patients 
understood the 
results very well 
or somewhat 
well, and 
pharmacist 
interpretations 
were correct just 
under 90% of the 
time. Pharmacists 
reached out to a 
physician in 4 
instances across 
56 patients. 
Nishimura et 
al., 2016 
United 
States 
To determine if 
physicians find 
clinical decision 
support alerts for 
pharmacogenomi
c drug-gene 
interactions 
useful and assess 
their perceptions 
of usability 
aspects that 
impact 
usefulness. 
A case scenario 
approach was use 
where the participant 
was responsible for 
prescribing dual anti-
platelet therapy. The 
participant was 
directed to select a 
therapy and then 
regardless of choice a 
pharmacogenomic 
alert for clopidogrel 
and the CYP2C19 
variant was shown. 
This was followed by 
a 15-item 
questionnaire and 
open-ended questions 
on their response to 
the alert. 
Fifty-five 
physicians at 
the University 
of Washington 
enrolled in the 
study. 58% of 
these were 
attending 
physicians. 
Respondents 
worked in 
major medical 
centers, 
outpatient and 
specialty 
clinics, and 
emergency 
departments. 
Physician response 
to the alert in an 
actual clinical 
interaction. 
Usefulness of the 
alert in general, 
quality of the alert's 
visual design, 
appropriateness of 
the alert in a clinical 
workflow, and 
usefulness of the 
pharmacogenomic 
content. 
40% of 
physicians would 
cancel and 49% 
would modify 
their initial order 
for aspirin or 
clopidogrel after 
seeing the alert. 
4% stated they 
would override 
the alert. 7% 
reported "Other" 
and responded 
they would 
contact a 
pharmacist.  
Close to 90% 
agreed or 
strongly agreed 
the alert was 
helpful, the text 
was helpful for 
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decision making, 
and that the alert 
came at the 
appropriate time. 
30% of 
physicians were 
unsure that 
pharmacogenomi
c data was useful 
for their practice. 
Nutescu et al., 
2013 
United 
States 
To determine the 
procedural 
feasibility of a 
pharmacist-led 
interdisciplinary 
service for 
providing 
genotype-guided 
warfarin dosing 
for hospitalized 
patients newly 
starting warfarin. 
Prospective, 
observational study. 
Patients that received 
genotype-guided 
warfarin therapy 
provided written, 
informed consent for 
use of their data and 
leftover genetic 
sample. Recorded 
information included 
time of initial 
genotype and consult 
order, time to results 
appearing in EHR, 
time to initial consult 
and genotype guided 
dose 
recommendation, 
warfarin doses.  
The EHR 
system for the 
University of 
Illinois - 
Chicago. 
Clinical dose 
recommendatio
ns are made by 
the 
pharmacogeneti
cs consult team. 
Adherence of the 
medical staff to 
doses recommended 
by the 
pharmacogenetics 
service. Acceptance 
of the dose 
recommended 
defined as within 
0.5 mg. 
A total of 353 
dose 
recommendations 
were provided 
for the 80 
patients enrolled. 
During the initial 
six months of the 
service, 73% of 
warfarin doses 
ordered by the 
primary team 
were within 0.5 
mg of the 
recommended 
dose by the 
clinical 
pharmacist on the 
pharmacogenetic
s service. There 
was a noted 
increase in 
adherence to the 
dose 
recommendations 
over time: 66% 
in months one 
and two, 76% in 
months three and 
fourth, and 80% 
in months five 
and six. 
Overby et al. 
2015 
United 
States 
Pilot study to 
assess the 
physician, 
technology, and 
Clinical experts 
helped develop 
hypothetical clinical 
case scenarios that 
Fifteen 
oncology and 
seven 
cardiology 
Assessments of 
clinical impact 
measured by 
prescribing uptake, 
Across both high 
and low 
actionable alerts, 
fellows used the 
48 
 
task 
characteristics of 
effective 
communication  
and clinical 
impact of using a 
prototype CDS 
system 
embedded in the 
EHR to deliver 
PGx information. 
prompted prescribing 
tasks, and revisions 
of scenarios that 
included presentation 
of PGx information. 
Each participant was 
presented with five 
scenarios. The third-
fifth were deployed 
in a pseudo-
randomized fashion.  
fellows 
practicing at the 
University of 
Washington. 
prescribing intent, 
and change in 
personalized drug 
dosing (PDD). 
gene specific 
resources 88% of 
the time and the 
alert message 
evidence 74% of 
the time. Sixty-
five percent of 
physicians 
changed the 
prescribed dose 
after using the 
PGx-CDS. A 
significant 
change 
(decrease) was 
only observed for 
capecitabine and 
mercaptopurine/t
hioguanine.  
Payne et al., 
2011 
United 
Kingdom 
To compare the 
preferences of 
patients and 
health-care 
professionals for 
the key attributes 
of a PGx testing 
service to 
identify a 
patient’s risk of 
developing a side 
effect 
(neutropenia) 
from the 
immunosuppress
ant, azathioprine. 
A discrete choice 
experiment through 
an online survey that 
consisted of five, 
four-level attributes 
resulting in 1024 
possible scenarios. 
This was done 
alongside a 
prospective 
randomized 
controlled trial 
(TARGET study). 
One hundred 
thirty-eight 
healthcare 
professionals 
(83% 
physician) with 
experience of 
prescribing and 
advising on 
azathioprine. 
The five attributes 
were level of 
information given, 
predictive ability of 
the test, how the 
sample is collected, 
turnaround time for 
a result, who 
explains the test 
result.  
Health-care 
professionals 
were willing to 
wait 2.2 days on 
average for a 1% 
improvement in 
predictive 
accuracy. They 
were willing to 
wait 8.9 days for 
high levels of 
information 
provision. 
Health-care 
professionals 
preferred the 
physician over 
the pharmacist in 
the delivery of 
results. They 
were willing to 
wait 9.5 days and 
give up 4.4% in 
predictive ability 
of the test. This 
percentage 
increased to 6.1 
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for the hospital 
doctor to deliver 
the result. No 
significant 
differences in 
how the sample 
is collected.  
Peppercorn et 
al., 2013 
United 
States 
To assess the use 
of the CYP2D6 
test for 
tamoxifen 
metabolism 
outside of 
clinical trials and 
the attitudes of 
community-
based oncologists 
and breast cancer 
specialists about 
testing among 
patients with 
breast cancer 
eligible for 
tamoxifen 
therapy. 
Anonymous cross-
sectional survey that 
evaluated knowledge 
of the CYP2D6 test, 
use outside of trials, 
requests by patients 
and third parties, and 
a response to 
hypothetical test 
results. Associations 
between practice 
setting and CYP2D6 
knowledge, use of 
the test for 
tamoxifen, and 
practice patterns 
were evaluated. 
Survey was piloted 
with oncologists at 
the Duke University 
Medical Center in 
Durham, NC. 
Final survey 
was mailed to a 
random sample 
of all breast 
cancer medical 
oncologists 
affiliated with 
the National 
Comprehensive 
Cancer 
Network 
(NCCNOs) and 
a random 
sample of 
community-
based 
oncologists 
(CBOs) from 
the American 
Society of 
Clinical 
Oncology  
Response to 
hypothetical test 
results presented 
through three 
scenarios regarding 
managing 
management of 
patients on 
tamoxifen who 
obtained 
commercially 
available CYP2D6 
results from an 
external source 
For a 
premenopausal 
woman with a 
poor metabolizer 
(PM) genotype, 
33% would make 
no changes, 
whereas 56% 
would change 
therapy. There 
were significant 
differences 
between 
NCCNOs and 
CBOs on what 
specific change 
would be made. 
66% of 
respondents 
made no change 
when it was a 
premenopausal 
woman with an 
intermediate 
genotype, 20% 
would change. 
The last case 
involved a PM 
postmenopausal 
woman and only 
14% of 
respondents said 
they would not 
change therapy.  
Peterson et al., 
2016 
United 
States 
Solicit clinician's 
perceptions of 
clinical utility, 
preparedness to 
effectively use 
Online survey design 
with questions based 
on a previous 
publication by Stanek 
et al and 
Clinicians at 
Vanderbilt 
University 
within 
cardiology, 
Responses to the 
question of which 
providers were 
responsible for 
clinical action with 
For the 
clopidogrel and 
CYP2C19 
scenario, 
cardiology and 
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PGx test results, 
and questions of 
responsibility for 
disclosure and 
clinical use of 
multiplexed 
results 
contributions by two 
authors. Two clinical 
scenarios were 
presented to 
determine which 
providers should be 
responsible for 
clinical action. 
primary care, 
and 
endocrinology 
who had 
previously 
ordered a PGx 
test in the 
implementation 
program or 
cared for a 
patient with a 
PGx result. 
Eighty percent 
of respondents 
were 
physicians. 
a pharmacogenomic 
result. 
non-cardiology 
providers agreed 
multiple 
providers should 
be individually 
notified of 
results, but less 
than 50% agreed 
the patient should 
be notified 
directly. Ninety 
percent of 
cardiology 
providers 
selected the 
specialist treating 
the medical 
condition and the 
80% selected the 
prescriber of the 
drug therapy 
affected by test. 
Ninety-five 
percent of non-
cardiology 
providers 
selected the 
prescriber of the 
drug therapy. 
Regarding who is 
responsible to act 
on the result, 
80% of 
cardiology and 
74% of non-
cardiology chose 
the specialist 
treating the 
condition to be 
responsible for 
acting on the 
result. Just above 
50% of both 
groups also chose 
the provider who 
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ordered the PGx 
test. 
Peterson et al., 
2016 
 
United 
States 
 
To investigate 
how physicians 
respond to an 
enterprise-wide 
PGx 
implementation 
utilizing either a 
clinicial decision 
support and a 
pharmacist-led 
surveillance 
system. 
 
In a new 
implementation 
program, coronary 
stent patients 
receiving clopidogrel 
were genotyped 
CYP2C19 variants. 
Poor and 
intermediate drug 
metabolizers were 
flagged and reported 
to attending 
cardiologists to see if 
alternative 
antiplatelet agents 
were prescribed. 
 
Prescribing 
decisions were 
tracted for 514 
patients with 
poor or 
intermediate 
drug 
metabolizer 
status of 2,676 
that received a 
coronary stent 
in the study 
period and were 
discharged on 
clopidogrel 
therapy. 
 
Time to a genotype-
tailored antiplatelet 
prescription within 
12 months of the 
stent procedure. 
Antiplatelet 
prescription was 
labeled as 
genotype-tailored if 
it matched the 
PREDICT program 
recommendations 
for CYP2C19. 
Interception rates 
from the pharmacist 
surveillance system. 
At 12 months, 
57.6% of poor 
metabolizers and 
33.2% of 
intermediate 
metabolizers 
received 
alternative 
treatement. 
CYP2C19 was 
the most 
predictive factor 
of prescribing 
changes. 
Pharmacist-led 
surveillance 
intercepted 481 
of 514 candidate 
patients for 
alternative 
therapy. 304 
patients were 
recommended for 
therapy change 
and 130 changes 
were made 
within 12 
months. 
St. Sauver et 
al. 2016 
United 
States 
To assess the 
perspectives of 
clinicians and the 
impact of PGx 
alerts on 
prescribing 
practices who 
received 
informational 
materials through 
a clinical 
decision support 
in the electronic 
drug prescribing 
system. 
In February 2015 
respondents were 
sent an email survey 
to understand 
perspectives on 
implementation and 
use of PGx testing in 
clinical practice. 
Once the survey was 
returned, the number 
of PGx-CDS alerts 
were extracted from 
the EHR.  
One hundred 
fifty-nine 
primary care 
physicians at 
the Mayo Clinic 
in Rochester, 
Minnesota. This 
physicians care 
for 1,013 
patients 
participating in 
the RIGHT 
Protocol. 
Perspectives on 
clinicians that 
remembered seeing 
a PGx alert. 
Clinician response 
to an alert if they 
received one. CDS 
alerts were grouped 
into two categories: 
alert recommended 
caution with the 
prescription or the 
alert recommended 
an alternate 
prescription. 
Thirty-six 
clinicians 
reported on their 
responses to the 
PGx alert. 12 had 
only positive 
response, 19 had 
only negative, 
and five reported 
both positive and 
negative 
responses. EHR 
and CDS data 
from 27 
clinicians and 50 
alerts were 
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eligible for 
inclusion. 26 
alerts 
recommended 
caution w/ 
prescription. 
Three of these 
resulted in a 
prescription 
change, 23 did 
not. 24 alerts 
recommended a 
prescription 
change. Seven of 
these resulted in 
a prescription 
change, 17 did 
not. 
Ubanyionwu 
et al., 2018 
 
United 
States 
 
To report the 
results of 
prescribers' 
responses to a 
PGx-based 
clinical decision 
support (CDS) 
alert designed to 
prompt TPMT 
status testing. 
 
Retrospective, chart 
review to evaluate 
prescriber 
compliance with a 
pretest CDS alert that 
warned of potential 
thiopurine drug 
toxicity resulting 
from deficient TPMT 
activity. 
 
The Mayo 
Clinic's 
Rochester 
campus 
electronic 
health record 
system between 
November 20, 
2014 and 
August 31, 
2015. 
 
The proportion of 
patients for whom a 
test to ascertain 
TPMT status was 
ordered and number 
of guideline-
supported doses 
ordered after CDS 
alert. 
 
Of 500 CDS 
alerts generated, 
101 cases of 
TPMT 
phenotyping or 
TPMT 
genotyping were 
ordered. Alert 
fatigue from 
alerts firing in 
cases of 
continuing 
therapy may 
contribute to this. 
24 patients were 
provided with 
thiopurine dosing 
recommendations
, only 12.5% 
received 
concordant doses 
Unertl et al., 
2015 
United 
States 
To describe the 
knowledge and 
attitudes of 
clinicians 
participating in a 
large 
pharmacogenomi
Semi-structured 
interviews. Subjects 
were recruited 
through email or in 
person and 
compensated for their 
time. Data collection 
Thirteen 
physicians and 
two nurse 
practitioners at 
Vanderbilt 
University. 
These 
Key themes 
categories and the 
multiple themes 
representing these 
categories. 
Three high-level 
theme categories: 
preparation and 
knowledge, PGx 
use in practice, 
future 
implementation 
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cs 
implementation 
program. 
continued until data 
saturation, when 
additional interviews 
yielded no significant 
new information. 
individuals 
came from 
either a primary 
care or 
cardiology 
practice. They 
were stratified 
by the usage 
patterns: <10 = 
low, between 
10 and 99 = 
medium, and 
>100 = high. 
challenges. 
Clinicians 
acknowledged 
complexity and 
unfamiliarity 
with 
representations 
and 
nomenclature 
that led to 
difficulties in 
using the data. 
Strong support 
for ongoing 
engagement with 
implementation 
team. Concerns 
included the 
long-term 
responsibility of 
actionable results 
and hand-offs to 
those outside the 
program. 
Walden et al., 
2015 
Canada To assess 
physicians' 
perception of 
PGx testing and 
their experience 
using the test 
results to help 
prescribe 
antidepressant 
and antipsychotic 
medication. 
Survey sent to 
physicians six to 
eight weeks after 
receiving a PGx 
report. This 
coincided with the 
first patient follow-
up visit at six weeks 
from baseline to 
allow time for the 
physician to decide if 
changes in 
medication should be 
made. 
One hundred 
sixty-eight 
Canadian 
physicians who 
ordered at least 
one PGx test for 
the prescription 
of a psychiatric 
medication. 
Psychiatrists 
(33.9%) and 
general 
practitioners 
(40.5%) 
constituted 
most 
respondents. 
Physician attitudes 
towards PGx testing 
were assessed using 
the 
Pharmacogenetics 
in Psychiatry 
Follow-up 
Questionnaire (PIP-
FQ). 
A vast majority 
of respondents 
agreed that 
genetic testing 
will become 
common 
standard in 
psychiatric drug 
treatment and 
were satisfied 
with the genetic 
information 
provided to them. 
Clinician 
scientist 
respondents 
(n=12) reported a 
statistically 
significant (p 
<0.001)  higher 
mean in their 
reported ease of 
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understand PGx 
information. 
Wegwarth et 
al., 2009 
Germany 
and 
United 
States 
To investigate 
oncologists' 
decision making 
on using PGx 
tests for cancer 
treatment and to 
examine cross-
cultural 
differences 
between the USA 
and Germany. 
A pilot study was 
used to reveal the 
cues which play a 
role in the decision to 
order a PGx test. 
These cues were then 
used in the main 
study which 
consisted of nine 
scenarios. To 
determine which 
information was most 
important and how it 
was processed three 
models were applied: 
the weighted additive 
model, the equal-
weighted model, and 
a simple sequential 
model. 
The pilot study 
consisted of 
seven US and 
12 German 
oncologists. 
The main study 
was comprised 
of 109 US and 
111 German 
oncologists. 
Whether 
respondents would 
use the test for 
making a treatment 
decision or not, and 
the type of 
information most 
influential in this 
decision.  
US oncologists 
opted for the test 
in 6.5 out of nine 
scenarios, and 
German 
oncologists in 5.4 
scenarios. The 
most influential 
information to 
US oncologists 
was the cost of 
the test, and the 
guideline 
recommendation 
of the test for 
German 
oncologists. 
When side 
effects of the 
therapy were 
described as 
more severe, a 
20% increase 
ordering of a 
non-guideline 
recommended 
test was noted. 
PGx = pharmacogenomics 
Hypothetical clinical case scenarios 
 Studies in this section are defined by their approach to engaging a provider in an exercise 
that mimics real-world clinical decision making in some form.  Of the nine studies included in 
this section, there are three main sub-sections that can be defined. These three sub-sections are: 
information seeking, prescribing tasks, and other. The first of these sub-sections, “information 
seeking” includes three studies that aimed to directly measure the time it took to complete certain 
tasks involving the use of pharmacogenomic information.23,26,41 All three qualitatively assessed 
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reactions to the information-seeking process either during or after the exercise. In addition to the 
time it took to complete the task, one study measured the number of searches and page 
navigation events that took place as the provider attempted to answer their question.26 The 
variability between the findings of each of the included studies was high given the inherent 
differences among clinical decision support systems (CDS) and study tasks. One study used two 
scenarios to gauge improvement in the time to complete from scenario 1 to scenario 2.41 These 
studies cut across physician specialties, from internists to cardiologists and oncologists, and 
included multiple disease states and/or pharmacogenes. The sample size was small for these 
studies, ranging from 6 to 10 physicians. Due to variability in the tasks, it is difficult to make 
comparisons between the studies. However, physicians spent between three and half to five 
minutes on the prescribing task and upwards of eight minutes on information-seeking.  
 The second sub-section, “prescribing tasks”, included three studies wherein the 
prescriber’s hypothetical actions taken when presented with pharmacogenomic information were 
evaluated.29,31,32 Variables measured in these studies included the percentages of physicians who 
would change a decision or initial orders based on new pharmacogenomic information, response 
to or dismissal of CDS messages, as well as evaluations of whether the alerts or information 
were helpful in decision making. All studies in this section were quantitative in methodology. 
The sample size was larger for this sub-section, ranging from 15 to over 200 physicians. Overall 
these providers agreed that the alerts were helpful and there was high utilization of the clinical 
decision support resource. Changes in decision making based on this gene specific information 
were noted in most of the cases. 
The third sub-section, “other”, included three studies which each had unique 
approaches.39,40,42 The first aimed to understand different objectives including an attitude 
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assessment of a CDS tool usability, the second evaluated the use of irrelevant genomic 
information by psychiatrists with differing experience levels, and lastly, a survey examined the 
inter-country differences as drivers of oncologist test ordering. Like the previous section, 
providers involved in the studies cut across specialties and quantitative outcomes were reported. 
However, the sample in one study included both physicians and pharmacists. Attitudes toward 
the CDS were moderately positive (42.3 out of 64), younger psychiatrists were significantly 
more likely to use irrelevant genomic information than their colleagues with more than 15 years’ 
experience, and US oncologists opted for testing more than their German counterparts.  
Prospective or retrospective real-world studies of prescribing/testing decisions 
This section includes seven of the 25 studies, five of which were prospectively designed 
and two that used a retrospective chart review methodology. This can be further broken down 
into two sub-sections: first, studies that explicitly stated the prescribers action being based on the 
recommendation of a pharmacist or pharmacist-led surveillance service,22,24,30,34 and secondly, 
those studies that either prospectively or retrospectively evaluated prescriber decision making 
based on a CDS alert37,38 or another form of communication, the type of which was not explicitly 
stated.46  
Among the four studies in the first sub-section, those where clinical recommendations 
either came directly from a pharmacist or from a pharmacist led pharmacogenomic service, the 
primary aim was to ascertain the frequency with which prescribers accepted these 
recommendations and for what types of patients (i.e., metabolizer status) did this occur. 
Prescriber response to the pharmacist recommendation was separated by the metabolizer status 
of the patient in two of the studies.24,34 Two studies30,46 also incorporated an evaluation of the 
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prescriber response over time and most study outcomes were based on at least six months of 
data. Study size ranged widely from actions taken on 18 patients up to decisions on 514. Two 
studies focused on genotype-tailored antiplatelet therapy, one on the dosing of warfarin, one 
focused on psychiatric medications, and one that cut across therapeutic areas. Acceptance of 
pharmacist recommendations overall was high, however lower rates can be seen when the 
recommendation from the pharmacist was to make a therapeutic modification.  
In the second sub-section the outcome of interest was not adherence to a pharmacist 
recommendation, rather it was adherence to an internal CDS system or interpreted results and 
guidance from the testing lab/company. Two of the three studies in this sub-section produced 
outcomes from a retrospective chart review to evaluate adherence to testing.37,38 Interestingly, 
both studies share additional similarities including a sole focus on TPMT testing and the use of a 
“pretest CDS alert”. This means that the CDS system, rather than guiding the provider on 
prescribing, informed them that testing is indicated prior to any initial dosing. Pre-test alerts 
resulted in about 25% of recommended tests being ordered in one study and 90% in another. 
High rates of modification in doses occurred when prescribers received an alert after the initial 
prescription.  
Cross-sectional quantitative surveys 
The cross-sectional quantitative survey section includes five studies that employ unique 
methodologies to measure response from providers involved in pharmacogenomics.28,33,35,43,44 
Given the uniqueness of each study, no sub-sections were developed here. 
One study was based on an actual implementation project across a series of community 
pharmacies.28 This study captured a holistic perspective from pharmacists not only on their 
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experiences with delivering pharmacogenomics but also their perceptions of the patients’ 
experiences as well.28 The survey of interest was offered after the testing of CYP2C19 and 
SLCO1B1 was complete and test results communicated.28 A discrete choice experiment was 
conducted along a randomized controlled trial involving use of azathioprine.43 This study 
examined the trade-offs healthcare professionals were willing to make across numerous variables 
including predictive ability of the test, wait time for results, and information provision.43 The 
third study in this section evaluated physician (both psychiatrists and general practitioners) 
attitudes toward pharmacogenomic testing for antidepressant and antipsychotic medications at 
the time of a patient follow-up visit, 6-8 weeks after test results were received.44  
The last two studies were conducted in two large-scale academic implementation 
programs for pharmacogenomics: Mayo Clinic and Vanderbilt University Medical Center 
(VUMC).33,35 The study from the Mayo Clinic’s RIGHT protocol assessed the positive or 
negative aspects of a pharmacogenomic alert.35 This study also included data similar to the last 
section that tracked the type and number of alerts that subsequently resulted in a prescription 
change.35 The VUMC study aimed to uncover perceptions of both cardiology and non-cardiology 
providers about who should be notified of the pharmacogenomic results and who should be 
primarily responsible for managing the patient.33 
The latter four studies had between 80 and 159 physician respondents while the former 
never explicitly stated the number of pharmacists responding to the survey.33,35,43,44 Rather, the 
reader is informed of the number of participating pharmacies (n=5) and the number of patients 
engaged by these pharmacists (n=69). The results of the DCE study revealed several interesting 
tradeoffs physicians were willing to make for higher levels of information and predictive ability 
of the test.43 There was rather strong agreement among cardiology and non-cardiology providers 
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regarding returning results to both the specialist treating and the original prescriber of the drug 
therapy, as well as agreement that the specialist should be responsible for acting on the result. 33 
Cross-sectional qualitative survey methods 
 Qualitative survey methodology uses less structured methodologies such as interviews, 
focus groups, or open-ended surveys. The use of in-depth interviews was the unanimous choice 
among researchers for studies included in this group.27,36,45 One focused on mental health 
providers and elicited specific reasons for and against utilizing test results as well as the 
advantages and disadvantages of testing more generally.45 This study contrasts to the other two 
in that a thematic analysis was not the intent of the findings. A second study targeted primary 
care physicians to understand more deeply the value and utility of pharmacogenomics, as well as 
its use to guide clinical decision-making.27 Participants here were also given complimentary 
testing kits for themselves and their patients. The last study included both primary care and 
cardiology providers and utilized a thematic approach in the analysis.36  
The number of interviews conducted range from 15 to 33 individuals across the studies. 
The nature of the qualitative methodology seemed to lend itself to a broader assessment of 
provider involvement with pharmacogenomics, rather than a narrow focus on a specific drug-
gene pair. Results of particular interest include the noted advantages of results for decision 
confirmation and reassurance, however there were perceived disadvantages including the use 
genomic results at the expense of clinical judgment and worries of handoffs to providers outside 
established implementation programs.36,45  
Quasi-experimental  
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 Quasi-experimental studies involve manipulating one or more variables, but without the 
random assignment of participants to one condition or the other. Only one study included in our 
search fit this criteria and thus was given its own section.25 Framing the study as a pilot, the 
authors designed a two-armed (physician vs. pharmacist-initiated testing) intervention trial with 
pre-post survey assessments of the primary care physicians involved in each arm. The survey 
results were supplemented by chart reviews of the 6-month follow-up period from the beginning 
of the trial. Six different tests (CYP2D6, -2C19, -2C9, VKORCI, HLA-B*1502, and SLCOB1) 
were offered and made available for ordering during the trial. Results from this study found that 
significantly higher levels test were ordered from the pharmacist in-house arm (48 of 63 total 
tests ordered) and physicians consulted pharmacists at nearly twice the rate in the in-house arm.  
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4. DISCUSSION 
This scoping review examined the characteristics of 25 peer-reviewed studies, published 
since the year 2000 and concentrated on illuminating the prevailing methodologies used to 
examine the active use of pharmacogenomics (PGx) in practice. The decision to identify 
methodologies used in implementing PGx in practice was a reaction to the saturation of the 
literature with cross-sectional health care professional awareness and attitude studies. A common 
thread in these awareness and attitude studies is that health care professionals find 
pharmacogenomics useful to patient care, but in most cases lack the requisite knowledge to 
deliver it effectively.8,15,16,47,48 While valuable, especially in the early stages of implementing a 
health innovation, these types of studies tend to lack elements that should be considered for 
sustainability, as outlined in the DSF.19 
Our content analysis of the study designs and methods identified five unique groupings that 
researchers had employed during the time frame of the search. This included hypothetical 
clinical case scenarios, real-world studies on prescribing/testing decisions, cross-sectional 
quantitative surveys, cross-sectional qualitative interviews, and quasi-experimental studies. 
Separating the studies into five-year blocks, a trend of an increasing number of studies fitting our 
inclusion criteria can be seen, with nearly 70% published in the last four years. Most of these 
studies produced quantitative outcomes and were conducted by researchers in the United States. 
Interestingly, our review did not include any studies where the genetic counselor was the health 
care professional involved in using pharmacogenomic information. 
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 The included studies demonstrate a continued focus on decision making within the 
confines of the EHR. Most studies of this nature came from the hypothetical case-based 
scenarios designed to mimic real-world practice. These types of studies fit well at the 
intersection of the three genomic sustainability constructs outlined at the beginning of this 
review: clinician education, CDS tools, and workflow integration.10 The importance of well-
designed CDS has been a central focus among leading implementation programs for 
pharmacogenomics. Research from groups such as the Clinical Pharmacogenetics 
Implementation Consortium’s (CPIC) Informatics Working Group provides suggestions best 
practices for integrating CDS with pharmacogenomics for clinical delivery.49 Other leaders in the 
field point to the importance and challenge of developing standardized representations of results 
and identifying the right person to receive a CDS alert.50,51 The feasibility of many of the studies 
included in this section is driven by the translation of pharmacogenomic information into a 
discrete data field that can be called upon when applicable. EHRs without this functionality 
make it impossible for prescribers to use this information efficiently.52 Given the variability 
between studies, future research on prescriber interactions with a with pharmacogenomic CDS 
should pursue comparative and longitudinal study designs to elucidate the most effective way to 
deliver this information. 
Additional findings from the review indicate that there has been a concerted effort from 
several ongoing implementation programs to understand who should be acting on 
pharmacogenomic information and how well these providers perform. These types of studies are 
crucially important as they provide the real-world program with a sense of “buy-in” from 
prescribers. This was typically achieved in one of three ways: by measuring adherence or 
compliance to a pharmacist- or CDS-based dosing recommendation, measuring engagement with 
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the platform and any medication changes without the recommendation aspect, or measuring 
ordering rates based on a pre-test alert to inform the prescriber that a test prior to any dosing is 
indicated. Following providers over time to see how their adherence behavior changes should be 
considered for studies in the future. A single cross-sectional assessment would likely miss this 
trend if applied in other settings. Clinician’s limited exposure to pharmacogenomics has been 
previously noted in the literature.7,15,47 This unfamiliarity with using the information may 
contribute to a hesitancy to adopt these suggestions immediately. Supplementing these types of 
studies with qualitative assessments of why adherence to recommendations was higher or lower 
would strengthen these studies and help the discipline identify areas to intervene and make 
improvements. 
There will be a continued need to communicate the value and validity of pharmacist or CDS 
based recommendations more broadly. Pharmacist leadership and involvement with crafting the 
delivery of pharmacogenomics in clinical care has been strong to date and continuing this trend 
should be maintained for new practice settings when feasible.5,12,13,53 The infrastructure of the 
individual institution or practice will most likely guide whether clinical decision support or 
pharmacist guided recommendation is most appropriate for delivering clinical 
pharmacogenomics. 
Outside of the formal implementation program, the feasibility of delivering 
pharmacogenomics through the pharmacist and a community pharmacy setting is an ongoing 
stream of research for the pharmacogenomics community.17,54,55 Two studies herein illuminate 
some of the operational considerations such as the time needed for a pharmacogenomic consult, 
perceived patient understanding, and the ability of the pharmacist to interpret this information 
correctly.25,28 Both studies were conducted by the same group of researchers and in the same 
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state, thus the broader generalizability of the findings may be limited. However, these are 
excellent models for future researchers to mimic and establish broader validity. Pharmacist 
engagement in pharmacogenomics has support from their largest professional organizations, the 
American Society for Health-System Pharmacists and the American Pharmacists 
Associations.56,57 Collaborative models of care with physicians, such as formal collaborative 
practice agreements, is likely the more sustainable path as consistent reimbursement for clinical 
pharmacy services remains elusive.58 Furthermore, the integration of the genetic counselor into 
the physician-pharmacist collaboration would enhance the comprehensiveness of the patient 
experience and should be experimentally explored in the future. 
The findings from our scoping review reveal a plethora of study designs, types of providers 
involved, and drug-gene pairs serving as the clinical scenario for consideration. Almost all 
studies from the scoping review included a physician sample, with only one study exclusively 
focusing on pharmacists. However, several physician specialties (oncology, cardiology, 
psychiatry, endocrinology, internal and family medicine) were included. While most decision 
making and prescribing is done by physicians, future research should aim to do the same 
regarding the pharmacist’s actual experiences with using and acting on pharmacogenomic 
information. This will help achieve one of the research directions of Volpi et al., to study the 
pharmacist as the “clinical champion” for pharmacogenomics.5   
The results of this review are not without limitations. First, the timeframe excluded 
studies published after 2018 and thus likely missed some of the most recent studies. Given the 
fact that 70% of the included studies were in the last four years, this is highly likely. Many of the 
studies herein were published from some of the most mature pharmacogenomic implementation 
programs in the world. The inclusion of many of these studies is likely due to the nature of our 
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research question and inclusion requirements. More work should be done to explore these same 
ideas in community practice. The nature of a scoping review does not allow for the synthesis of 
results across studies and thus this was not our aim. However, the hope is that this review will 
provide the research community with a keener eye for trends and specific research questions that 
may lend themselves to such an exploration. 
In summary, this scoping review provides the pharmacogenomic research community 
with a compilation of the studies from the turn of the century that have aimed to collect data on 
the experiences or actions of health care professionals engaged in using pharmacogenomic 
information. We further focused the review on the methodologies employed by the authors and 
broke this down into five separate categories. The interactions of providers with clinical decision 
support systems and adherence to therapeutic recommendations represented many of the 
included studies. A broad thematic analysis of the methods and findings provided structure to a 
discussion that will hopefully guide further research on those factors needed for successful 
integration of pharmacogenomics into clinical care.  
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APPENDIX 1. Search Strategy 
 
 MEDLINE® MeSH® search string was as follows: 
(((((((("Pharmacogenetics"[Mesh]) AND "Health Personnel"[Mesh])) OR 
(("Pharmacogenetics"[Mesh]) AND "Attitude of Health Personnel"[Mesh])) OR 
(("Pharmacogenetics"[Mesh]) AND "Genetic Counseling"[Mesh])) OR 
(("Pharmacogenetics"[Mesh]) AND "Education"[Mesh])) OR (("Pharmacogenetics"[Mesh]) 
AND "Surveys and Questionnaires"[Mesh])) OR (("Pharmacogenetics"[Mesh]) AND 
"Physicians"[Mesh])) OR (("Pharmacogenetics"[Mesh]) AND "Pharmacists"[Mesh]).  
 
Embase® Emtree® search string was as follows: 
('pharmacogenetics'/exp AND 'health care personnel'/exp AND [embase]/lim OR 
('pharmacogenetics'/exp AND 'health personnel attitude'/exp AND [embase]/lim) OR 
('pharmacogenetics'/exp AND 'physician'/exp AND [embase]/lim) OR ('pharmacogenetics'/exp 
AND 'pharmacist'/exp AND [embase]/lim) OR ('pharmacogenetics'/exp AND 'genetic 
counseling'/exp AND [embase]/lim) OR ('pharmacogenetics'/exp AND 'education'/exp AND 
[embase]/lim) OR ('pharmacogenetics'/exp AND 'questionnaire'/exp AND [embase]/lim)) AND 
([article]/lim OR [article in press]/lim OR [short survey]/lim) AND [english]/lim AND 
[embase]/lim AND [2000-2019]/py.  
 
73 
 
APPENDIX 2. - STROBE Statement—Checklist of items that should be included 
in reports of observational studies 
 
 
Item 
number 
Recommendation 
Title and Abstract 1 
(a) Indicate the study’s design with a commonly used term in the title or 
the abstract 
(b) Provide in the abstract an informative and balanced summary of what 
was done and what was found 
Introduction 
Background/rationale 2 
Explain the scientific background and rationale for the investigation 
being reported 
Objectives 3 State specific objectives, including any prespecified hypotheses 
Methods 
Study design 4 Present key elements of study design early in the paper 
Setting 5 
Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Participants 6 
(a) Cohort study—Give the eligibility criteria, and the sources and 
methods of selection of participants. Describe methods of follow-up 
 
Case-control study—Give the eligibility criteria, and the sources and 
methods of case ascertainment and control selection. Give the rationale 
for the choice of cases and controls 
 
Cross-sectional study—Give the eligibility criteria, and the sources and 
methods of selection of participants 
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(b) Cohort study—For matched studies, give matching criteria and 
number of exposed and unexposed 
 
Case-control study—For matched studies, give matching criteria and the 
number of controls per case 
Variables 7 
Clearly define all outcomes, exposures, predictors, potential confounders, 
and effect modifiers. Give diagnostic criteria, if applicable 
Data sources/ 
measurement 
8* 
 For each variable of interest, give sources of data and details of methods 
of assessment (measurement). Describe comparability of assessment 
methods if there is more than one group 
Bias  
(NOT USED) 
9 Describe any efforts to address potential sources of bias 
Study size  10 Explain how the study size was arrived at 
Quantitative variables 
(NOT USED) 
11 
Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
Statistical methods  
(NOT USED) 
12 
(a) Describe all statistical methods, including those used to control for 
confounding 
(b) Describe any methods used to examine subgroups and interactions 
(c) Explain how missing data were addressed 
(d) Cohort study—If applicable, explain how loss to follow-up was 
addressed 
Case-control study—If applicable, explain how matching of cases and 
controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking 
account of sampling strategy 
(e) Describe any sensitivity analyses 
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1.  BACKGROUND 
From 2012 to 2016, only 1.75% of genomics-related grants included the formal use of an 
implementation science framework.1 This equates to a total of four grants, all of which used the 
same framework, Everett Roger’s Diffusion of Innovation.2 The Center for Disease Control and 
Prevention’s (CDC’s) Public Health Genomics Knowledge Base identified 283 articles published 
in 2014 where implementation science has been applied to genomic medicine.3 However, the 
inclusion criteria did not specify that a formal implementation science approach must be taken, 
rather that the studies “contributed to our understanding of the implementation of genetic/-omic 
testing…”.3 In fact, what was discovered was that very few studies actually incorporated a 
theoretical framework from implementation science.3  
In late 2018 the CDC Office of Public Health Genomics blog made an urgent call for the 
integration of implementation science in genomic medicine. They highlight that although an 
evidence base is critical, we must also understand “what factors contribute to the success or 
failure of a genomic application within a particular setting”.4 A recent “priority-setting” study 
identified 28 constructs of importance for genomic medicine sustainability.5 Several of the top-
ranked constructs have direct implications for the clinical delivery of pharmacogenomics:  a need 
for expanded genomic education, addressing a lack of available genomic-focused clinical 
decision support (CDS) tools, and improving the integration of genomic information into clinical 
workflow. In fact, the sixth-ranked construct important for genomic medicine sustainability was 
the expansion of implementation science research.5  
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Evidence supporting the top rankings of these constructs include many previous studies 
that focus on the need for robust provider knowledge and seamless integration of information 
into the workflow. These issues have been consistently recognized as part of best-practice when 
implementing pharmacogenomics, a leading example of genomic medicine and the science of 
identifying genetic variants that may influence the safety or effectiveness of a drug in a patient.6-8 
However, as mature and advanced programs still face challenges in this area, it is not difficult to 
imagine that more pharmacogenomic-naïve health care settings will struggle with these 
insufficiencies even more.9-15 Formal training for providers in pharmacogenomics has been 
reported as low as 11% for physicians, and 17% for pharmacists.9,10,14 More recent work has 
qualitatively explored the ongoing physician needs and suggestions for improvement regarding 
pharmacogenomic clinical decision support (CDS).15 The nuances of which will require 
thoughtful design to achieve the seamless integration with current clinical workflows. On a 
positive note there is consistency throughout the literature that both physicians and pharmacists 
have favorable attitudes toward the use pharmacogenomics in patient care, but the confidence to 
use these results appropriately remains an issue.9,11,16-18 
Leaders in the implementation of pharmacogenomics recently put forth some ‘lessons 
learned’ and ‘research directions’ needed for the field, including several aligned with these 
sustainability indicators.19,20 Two particularly applicable ‘lessons learned’ for clinical 
implementation of pharmacogenomics are the importance of “stakeholder alignment and 
transdisciplinary teams” and the need for a “standardization of local factors (e.g. population, 
clinician workflow, and resources)”.19 Transdisciplinary teams have been driving 
pharmacogenomic implementation thus far, with both senior pharmacist and physician providers 
acting as successful program leads.21-25 Advancing health system pharmacogenomics will be 
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improved by identifying an appropriate, local ‘clinical champion’ and aligning transdisciplinary 
stakeholders based on the resources of the that context.19 Echoing the tone of the CDC, the 
application of implementation science can operationalize the ‘standardization of local factors’ by 
the “collection of data on dissemination and implementation from early sites of adoption using 
validated frameworks”.19 Despite sparse use of validated frameworks to date, a relationship 
between implementation science and genomic medicine has continued to develop.3,5,26-30 
Applying an implementation science methodology is essential for advancing pharmacogenomics 
in local health system contexts, many of which will have fewer resources than previous 
implementation programs. 
The current need from the pharmacogenomic research community is to answer the call 
for more integration of implementation science into genomic medicine from the CDC and 
leading clinical implementers. As such, our objective is to provide a qualitative assessment of 
perspectives and potential strategies for clinical pharmacogenomic implementation from a 
sample of early adopter leadership in the field. To accomplish this goal and to pursue a focus on 
the constructs needed for the sustainability of genomic medicine, we have applied the 
Consolidated Framework for Implementation Science (CFIR)31. The CFIR is comprised of 39 
constructs across five domains and is described by its developers as a “meta-theoretical” 
framework that can guide an understanding of where and why an intervention works.31 With the 
application of a validated framework, we aim to move the field toward a more robust 
understanding of local factors to enable success in additional settings.19   
 
 
 
 
79 
 
 
 
 
2.  METHODS 
Study design 
 Semi-structured, in-depth interviews were used as the specific methodology for this 
study. In-depth interviews have been suggested for use in the examination of the CFIR 
‘reflecting and evaluating’ (Process domain) constructs.29 They are also critical to uncovering 
insights for the translation and dissemination of an intervention in resource constrained 
environments, such as health care.29,32 The study was approved by the University of Mississippi 
institutional review board (Protocol #19x-206). 
Study population and sampling strategy 
Leaders involved at sites that have implemented pharmacogenomics were targeted for 
interviews using a purposive sampling design. Inclusion criteria include professional credentials 
of a physician (MD or DO), pharmacist (PharmD or RPh), or a clinical research scientist (PhD), 
and current or previous leadership involvement in an active pharmacogenomic implementation 
project. An initial list of potential respondents was brainstormed among two authors (NK and 
JH) according to one author’s (JH) experience as a member of the pharmacogenomic leadership 
team at their home institution. Individuals from 18 unique organizations were initially identified, 
with some organizations having two potential respondents. In instances where two individuals 
from one institution were identified, authors ensured that these respondents had differing 
professional credentials (i.e. MD and PharmD) and played differing roles in the implementation 
of pharmacogenomic programs. 
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Interview guide development 
An adapted version of the CFIR semi-structured interview guide, focusing specifically on 
the Process domain (cfirguide.org), was deployed in this study and is available in Appendix 1.33 
The Process domain is made up of the four constructs: planning, engaging, executing, plus 
reflecting and evaluating. The engaging construct is then further broken down into six sub-
constructs: formally appointed implementation leaders, opinion leaders, champions, key 
stakeholders, innovation participants, and external change agents.31 The Process domain was 
chosen for two reasons. First, its constructs, and sub-constructs best fit the study objective and 
ultimate intention to improve the long-term sustainability of genomic medicine. Secondly, the 
IGNITE Common Measures Working Group (CMG) recently evaluated the CFIR for its 
potential contribution to genomic medicine and included three of the Process domain constructs 
(engaging, executing, and reflecting & evaluating) in its list of highest priority CFIR constructs 
for genomic medicine implementation.29 Table 1 shows each construct, sub-construct, and 
corresponding definitions provided in the CFIR Codebook.31  
The constructs and sub-constructs of the CFIR Process domain are described as the 
“essential activities of the implementation process…[that] can be accomplished formally or 
informally…in any order…[and] can be revisited, expanded, refined, and re-evaluated.”31 The 
domain is linearly designed starting from the Planning construct through Engaging and 
Executing and finishing at the Reflecting & Evaluating constructs, yet the framework authors 
realize a real-world implementation will not always move this way. For example, new planning 
activities may be necessary as ideas come to light during other execution phases. 
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The CFIR guide was written using present, future, and past tense at different points. For 
our purposes, some of the included questions were edited to focus on a retrospective evaluation 
since many programs were implemented several years ago. For example, in the Reflecting & 
Evaluating domain, the question “Will feedback be elicited from staff? From individuals served 
by your organization?” was replaced with “Have you collected structured feedback from clinical 
staff on their experiences with pharmacogenomics?”. The initial guide was drafted by NK, 
reviewed and edited by MR and JH, and approved by all authors before use. The interview guide 
was pre-tested in a question – response – feedback format with a clinical implementer of 
pharmacogenomics whose responses were then ineligible for analysis. Several questions were 
removed following this pre-test because the questions were deemed either irrelevant or 
potentially confusing to respondents. 
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Table 1. Process domain construct and sub-construct definitions 
Construct Definition 
Planning 
The degree to which a scheme or method of behavior and 
tasks for implementing an intervention are developed in 
advance and the quality of the schemes or methods 
Engaging 
Attracting and involving appropriate individuals in the 
implementation and use of the intervention through a 
combined strategy of social marketing, education, role 
modeling, training, and other similar activities 
Formally appointed 
implementation leaders 
Individuals from within the organization who have been formally 
appointed with responsibility for implementing an intervention as 
coordinator, project manager, team leader, or other similar role 
Opinion leaders 
Individuals in an organization who have formal or informal 
influence on the attitudes and beliefs of their colleagues with 
respect to implementing the intervention 
Champions 
Individuals who dedicate themselves to supporting, marketing, and 
driving through an implementation, overcoming indifference or 
resistance that the innovation may provoke in an organization 
Key stakeholders 
Individuals from within the organization that are directly impacted 
by the innovation, e.g., staff responsible for making referrals to a 
new program or using a new work process 
Innovation participants 
Individuals served by the organization that participate in the 
innovation, e.g., patients in a prevention program in a hospital 
External change agents 
Individuals from within the organization that are directly impacted 
by the innovation, e.g., staff responsible for making referrals to a 
new program or using a new work process 
Executing 
Carrying out or accomplishing the implementation according 
to plan 
Reflecting & Evaluating 
Quantitative and qualitative feedback about the progress and 
quality of implementation accompanied with regular 
personal and team debriefing about progress and experience 
 
Data collection 
Once the sample of potential participants was finalized, individuals were invited via 
email and provided with a link to a demographic survey (Qualtrics, Provo, Utah) and scheduling 
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poll (Doodle, Zurich, CH) (Appendices 2 and 3). A second “reminder” invitation was sent out 
one week after the first if there is no response. These individuals were then contacted and 
successfully interviewed. No incentive was offered. 
Data analysis  
Analysis of the final transcripts utilized resources and methodology from the CFIR 
website (cfirguide.org).34 The CFIR codebook provides a definition of each construct and sub-
construct as well as inclusion and exclusion criteria for respondent statements. The definitions 
provided in the codebook were used to place verbatim quotes in the appropriate construct or sub-
construct. Since the question guide was based on the CFIR Process domain, most often the data 
were coded in the same construct as the corresponding question. However, at times, the elicited 
response was better coded in another construct. The constant comparative approach was used to 
compare each new transcript with one another to inductively identify thematic material within 
the constructs and sub-constructs.32 Authors NK and JH read each transcript in full twice. A third 
read through of the transcripts was done to identify which individual quotes best represented the 
thematic material. No disagreements occurred that required the mediation by a third author.  
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3.  RESULTS 
 Twenty individuals were initially contacted to participate in the interviews. Two of these 
individuals were unable to participate but recommended a colleague from their institution that 
they felt fit the inclusion criteria. Seventeen individuals completed both the screener survey and 
the subsequent in-depth interview. The remaining three individuals were not interviewed because 
data saturation had already been achieved. Figure 1 presents the results of the demographic 
survey. A little over half of the respondents were pharmacists (PharmD or RPh), while the 
remaining participants were either physicians or clinical research scientists. Most participants 
were CPIC members and came from academic institutions and/or institutions with at least three 
years of pharmacogenomic implementation experience. The institutions represent by the 
interview subjects mostly engage in single-gene and panel genotyping, as compared to 
sequencing, and just under half have implemented a preemptive model of testing. 
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Figure 1. Interviewed individuals’ demographics. PGx, pharmacogenomics; CPIC, Clinical Pharmacogenetic 
Implementation Consortium; IGNITE, Implementing Genomics Into Practice; eMERGE, Electronic Medical 
Records and Genomics; PGRN, Pharmacogenomics Research Network; PharmVar, Pharmacogene Variation 
Consortium. Some participants may hold more than one professional credential (MD/DO, PharmD/RPh, and PhD). 
 
Content Analysis 
 In the following sections interview participant responses to each of the constructs of the 
Process domain will be outlined. These findings from the CFIR Process domain should be read 
as an anecdotal guide for future managers of similar implementation programs. A summary of 
the key themes can be found in Table 2. 
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Table 2. Summary of key themes from constructs and sub-constructs of the CFIR Process 
domain 
CFIR Construct Key Themes 
Planning 
• Define leadership and engagement with physicians 
• Determine where pharmacogenomics is already used and clinician 
workflow needs 
• Smart small and get and early win 
• Formal vs. informal oversight structure 
Engaging 
Sub-
constructs 
Formally appointed internal 
implementation leaders   
• Multi-disciplinary approach 
• Dedicated information 
technology (IT) full-time 
equivalents (FTEs) 
Opinion leaders 
• Support from top leadership or 
visionary clinician 
• Cultural/organizational change 
Champions • Different champions for different 
clinical services 
Key stakeholders 
• Informal, high-touch approach 
• Utilizing pharmacists for 
knowledge and communication 
• Lack of formal education 
• The patient case 
Innovation participants 
• Engagement through the patient 
portal 
• Patient referral 
External change agents 
• CPIC  
• Peer organizations with similar 
EHR systems  
Executing 
• Lack of dedicated FTEs for pharmacogenomics 
• Feedback and adjustments to the clinical workflow  
• Creating a culture of resilience 
Reflecting & 
Evaluating 
• Prevailing goals for many was simply to get the program up and 
running 
• Process metrics (alerts fired, tests ordered, adherence to alerts) 
prioritized over outcome studies 
 
Planning construct 
One of the key themes in the Planning construct was the need to have defined leadership 
and engagement with physicians early on. As one scientist participant said, “Administrative 
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support is definitely something that was instrumental. The hospital administration gave the 
financial support and said, ‘You have a year, here’s some money to get started. Then it needs to 
sustain itself.’” (Scientist)  
Another important finding was the need to understand where pharmacogenomics was 
being used and optimizing workflow. A pharmacist participant said, “Over the past year, we’ve 
spent the majority of the time trying to determine where pharmacogenomics is already being 
used in practice and focusing on optimizing the processes that are being employed.” 
Understanding this will likely enable implementers to lock in one of our key themes of getting an 
“early win”: One of the biggest pitfalls that early programs in pharmacogenomics can do is 
oversell themselves. You're doing something novel. You need to have that win early on, so that 
people know that you can get something done.” (Pharmacist) 
There are mixed signals about what type of oversight structure is most appropriate and 
how this should evolve. More specifically, one respondent said, “When we started, we very 
quickly got a formal [committee] structure into P&T. That committee lasted about two years. 
Then, the personalized medicine [group] kind of took over as the oversight”.(Pharmacist) Some 
participants noted informal processes that have seemingly worked well, while others have 
struggled without formal oversight in place. A pharmacist participant shared this, “Hopefully we 
will have one [oversight committee] in the near future…because there's no formal group right 
now…for the new drug-gene pair I'm trying to implement I think I have six different committees I 
have to present in front of.”  
Engaging construct 
 The Engaging construct is the only one that contains specifically identified sub-
constructs. The major thematic points in each sub-construct will be discussed in turn.  
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Formally appointed internal implementation leaders 
Since many of the participants were themselves the “formally appointed internal 
implementation leader”, the interview guide questions were focused on high-level support 
broadly and where interview participants said they wished more support would come from. At 
more advanced institutions, formal leadership for genomic medicine has become engrained in the 
culture. A physician participant stated, “It goes without saying that the administration has to 
understand what it is we’re doing…but genomics implementation has been represented on the 
clinical strategic plan for years. So, we've gone through a cultural shift about how to use 
genomic information, so we don't have to go to administration to make a sell.” (Physician) 
IT professionals were also frequently mentioned as being a crucial component to 
implementation leadership. However, according to participants there were not enough of them. 
In particular, a pharmacist said, “Essentially all of our precision medicine initiatives are based 
on trying to use the EHR to its best effect. [This] could be farther along if we had more support 
for those people. [Those] in charge of the EHRs are overwhelmed with work, overwhelmed with 
emergencies, overwhelmed with fixing problems rather than working on strategic solutions.” 
(Pharmacist) 
Opinion Leaders 
 Several participants noted that institutional  leadership and often a visionary clinician 
with widespread respect was instrumental in the uptake of pharmacogenomics at their institution. 
As one participant put it, “Having institutional leadership from people like deans, CEOs, and 
whatnot, was incredibly helpful. For specific drug-gene interactions, I think having buy in of 
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either the division chief or other clinical champions in that area has been really helpful.” 
(Physician)  
Beyond specific individuals, a “systems” mindset was advocated for by one participant 
that reflected a broader finding that influence is better achieved with a cultural shift by saying, 
“Well, I don't think it's one individual. I think you really must think broadly. I'm a systems 
person, you're still going to have to have the systems in place that are really going to support 
being able to implement effectively.” (Physician)  Several participants, also noted the integral 
role and leadership of pharmacists in the implementation of pharmacogenomics. One participant 
explicitly noted the level of influence pharmacists have at their institution: 
“Our physicians tend to trust the opinions of our pharmacists about how to manage 
drug therapy. So, if the pharmacists hadn’t been on board, the physician probably 
wouldn’t have gone for it. The pharmacists are really the ones who make a lot of 
detailed decisions on how to adjust drug therapy, so if they hadn’t been on board, we 
wouldn’t have been able to do the implementation” (Pharmacist) 
Champions 
  The major theme herein was that engagement with a clinical champion is needed on both 
an institutional level, and an individual service level. One participant said, “I think in any clinic 
that you want to use a pharmacogenetic test, there needs to be a clinician champion there. It 
takes clinician buy-in and not just somebody saying ‘Oh, we have a pharmacogenetic test here 
we are implementing, and you can use it.” (Scientist) These physician champions were also 
useful in promoting pharmacogenomics beyond their own service as one participant described, 
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“Several of our docs come to mind right away because they’ve been champions outside of their 
own division.” (Pharmacist)  
Key Stakeholders 
This sub-construct elicited one of the longest discussions in the interview. An informal, 
high-touch approach to communication was consistently described by participants as successful 
and in their opinion the best approach to engagement of key stakeholders. A Physician 
participant stated, “We basically use more of a carpet-bombing approach…so we present it at 
department meetings, we present it through CME, there are online opportunities where we can 
present this type of information.” (Physician). A clinical pharmacist embedded with a physician 
was seen by several participants as a “catalyst” for encouraging use. A pharmacist leader said, “I 
utilized our clinical pharmacist first to really learn about the services, the clinicians, and try to 
build upon the relationship that was already established with the pharmacy department in those 
areas … I was able to be connected by someone that they already knew and trusted.” 
(Pharmacist) 
 Few participants acknowledged formal education initiatives for clinicians, and those that 
did, said this was typically directed at pharmacists rather than physicians. As one participant 
mentioned, “It's difficult for physicians to commit to formal training ...” (Physician). Lastly, the 
power of the patient case, that matched patients of clinical staff, was mentioned often as a 
noticeable influence. As another participant stated, “I think the first thing that was important was 
[for] someone to hear a case report and say, ‘Oh, you know I have ten patients I can [think] of 
that are in that exact same boat.’ So, I think after your first win, you become more confident.” 
(Pharmacist) 
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Innovation Participants 
 This discussion focused on how to directly engage with patients and through this, provide 
education that may drive their own engagement with providers. A pharmacist participant said, 
“We are hoping to have more engagement with patients through the electronic patient portal 
where we can actually return results with associated education information…and potentially talk 
to them about their results...” (Pharmacist) In line with this, a few participants noted the success 
of patient self-advocacy for testing saying, “Getting the patient to advocate to their provider, in 
a lot of ways would be more effective. Right now our model is relying on providers…but if you 
are advertising to patients, and they find it interesting, and they ask the provider about it, it's 
going to be difficult for the provider to ignore.” (Pharmacist)  
External Change Agents  
Widely cited by nearly every participant was the role of CPIC members and the 
accompanying guidelines produced by the group. As one physician said, “I’d say CPIC 
guidelines have been enormously helpful. Having a guideline written by experts outside of 
[redacted]. That external validity of the summary of the literature, and with a stamp that this is a 
high level of evidence, is really helpful.”(Physician) The role of peer institutions with similar 
EHR programs was also identified by a few participants as a positive influence on their success. 
A pharmacist participant said, “You need someone whose been there and done it to ask some 
questions of, particularly if they’re on your same EMR platform, that’s hugely helpful. 
(Pharmacist) Table 3 below includes additional verbatim quotes from the Planning construct and 
each of the Engaging sub-constructs. 
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Executing Construct  
 A nearly ubiquitous issue in this part of the discussions was the issue of EHR 
improvements and IT personnel availability. A pharmacist participant said, “I think the biggest 
issue is there is no dedicated IT FTE for pharmacogenomics. It's me borrowing people's time to 
do clinical decision support. So it goes into a bucket with every other IT request and things 
sometimes move quickly, things sometimes move slowly.” (Pharmacist) Tangentially related to 
this was the importance getting provider feedback regarding the workflow changes being made 
with the implementation of pharmacogenomic testing programs. Frustration with a lack of this 
was described by a participant:  
“I think failure to understand the clinical infrastructure is the biggest difficulty and my 
big frustration. My suggestion is to have the clinician champions go through and map the 
process from beginning to end because otherwise trying to implement a program that is 
not consistent with clinical practice, how things happen on a day to day basis…it just 
does not work.” (Physician) 
Understanding current workflow is crucial for effective integration of a new technology 
like pharmacogenomics, but several participants emphasized incorporating resilience into an 
implementer’s mindset. In this case, the term resilience here is best explained through this quote: 
“So, one of the first early lessons that I learned was just because you think you might use this in 
this particular service, they may have other ideas. So, one, you have to learn you might have to 
be patient, an avenue will open up [with] someone else who you didn’t even expect to step 
forward”. (Pharmacist) 
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Reflecting and Evaluating Construct  
 Thematic material in this construct was dominated by the finding that most programs had 
few goals beyond the directive to put a pharmacogenomics program into place. As one scientist 
mentioned, “They wanted to launch a pharmacogenomics service that would be helpful to 
clinicians and beneficial to patients. They didn’t feel like they needed to do it as a research 
project to prove outcomes or to prove cost effectiveness. They really just wanted to get it into 
clinical care first and foremost.” (Scientist) The “get it going” mentality seemed to be driven by 
safety at its core, as a pharmacist mentioned, “The goal of the program, the primary goal, is 
patient safety focused- or, medication safety focused.” (Pharmacist) 
In the absence of traditional clinical outcomes, there were other important process 
metrics that were incorporated into many programs. According to a pharmacist participant: 
“We did have some quantitative goals. We still do. We’re supposed to be showing that we 
have a higher percentage of prescribed drugs that are informed by pharmacogenetics, 
basically every year. But we did leave the objectives of the protocol quite broad and 
loose so that we would be able to continue to do the implementation without necessarily 
meeting very hard specific goals.” (Pharmacist)  
Table 4 below includes additional verbatim quotes from the Executing and Reflecting & 
Evaluating constructs. 
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4.  DISCUSSION 
This study represents one of the first primary data studies to qualitatively assess the 
perspectives of the leading voices in the clinical implementation of pharmacogenomics. Also, 
this is the first study to apply the rigor of an implementation science framework to 
pharmacogenomics. The core finding from the Planning construct was the idea that for 
successful implementation you must first do the appropriate due diligence on the clinical services 
and clinicians themselves prior to engagement. Following from this, several participants noted 
the importance of getting an “early win” to demonstrate to leadership that you can accomplish 
something tangible. It is also important to recognize the limitations of pharmacogenomics at your 
institution. A narrow, high-evidence focus will prevent a novice program from overselling and 
causing frustration in the future. The discussion of formal oversight also brought to light several 
important considerations. First, oversight covered the spectrum from formal committee to very 
informal, ad-hoc processes. However, it is important to note that there always remained some 
type of process. While it is unsurprising that newer programs may lack formal oversight, it was 
surprising to note that some of the most mature programs also lacked formal oversight. This 
seemed to be a product of pharmacogenomics folding into larger genomic initiatives with their 
own oversight processes.  
Across the sub-constructs of the Engaging construct there was a clear focus on the 
importance of institutional leadership supporting the implementation. This took shape through C-
suite executives who found particular value in pharmacogenomics, visionary clinicians, or in a 
98 
 
broader sense, a cultural shift to one where genomics was integral to all clinical care. At a more 
detailed level, participants widely noted that having a clinical champion in each service was 
essential to communication with the broader clinical network. Having a single individual to 
contact who then forwarded the information to colleagues was both successful and timesaving. 
However, this did not always have to be a physician-to-physician conversation. Many 
participants noted that they utilized the clinical pharmacist on service as a communication 
conduit to prescribers. From both pharmacists and physicians, there was strong opinion that all 
pharmacists should have some tacit knowledge of pharmacogenomics and be ready to interact 
with any prescriber when needed. 
The lengthy discussions on provider communication led to the ubiquitous opinion that 
informal, high-touch interactions were optimal. Terms such as “carpet-bombing” and “traveling 
roadshow” quickly showcase this sentiment. This was typically operationalized through grand 
rounds, lunch-and-learns, and even the classic “water-cooler” conversation. The importance of 
the patient case or the patient-driven referral was also a catalyst of provider engagement in 
pharmacogenomics. 
The Executing construct discussion centered around clinical decision support and clinical 
workflow. A common refrain was the need for more dedicated pharmacogenomic FTEs in the IT 
profession. Interfacing these individuals with more frequent clinical feedback on CDS language 
is essential to more effective workflow. Resilience should also be a part of every implementer’s 
toolkit. Perspectives from our participants indicated that even though a first attempt might fail, 
either opinions in the clinical service may change or a service you did not expect might come to 
you. 
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The Reflecting & Evaluating construct revealed a prevailing focus on patient safety and 
programmatic goals to simply establish and maintain a clinical pharmacogenomic service. 
Explicit data collection and measurement that did exist were not targeting clinical or economic 
outcomes, but rather they were process-based metrics for how pharmacogenomics was being 
used and how providers were responding to the addition of pharmacogenomic decision support 
alerts in the EHR. In some instances, these initial goals were simply to move pharmacogenomic 
results into discrete data fields and enable metric tracking. This is an essential step towards 
outcomes-based studies that reflect real-world clinical practice and decision making.  
This study used a popular implementation science framework, the CFIR, to address  
several issues, including the need for greater clinical education in genomics and improvements in 
clinical workflow and decision support, that were identified as important for the sustainability of 
genomic medicine and pharmacogenomics. We decided to focus our efforts on the foundational 
concept of sustainability in implementation science because it has received increasing attention 
as one of the most important, yet more misunderstood foundations of implementation science.35 
The study is somewhat limited due to the unbalance in the professional credentials of the 
respondents. This unbalance is, however, indicative of the current leadership and programs in the 
field. Also, focusing only on the CFIR Process domain excludes the potential application of other 
CFIR domains to this topic. Future research should explore other CFIR domains for their insights 
into clinical pharmacogenomic implementation.  
Our decision to study the CFIR Process domain and its operationalization herein can be 
further understood by connecting this domain with sustainability. Sustainability has been 
conceptualized not just as an outcome or metric of a successful implementation, but also as a 
cyclical “change process” that provides adaptability in pre-implementation stages such as 
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planning and organizational support, as well as a concomitant process to the implementation 
itself .36,37 Indicators of sustainability have been operationally defined as maintenance, 
institutionalization, and (infrastructure) capacity building.38 Capacity-building in the 
sustainability planning model is represented by factors that apply to both physical and human 
infrastructures which include: structures and linkages, champions and leadership, resources, 
policies and procedures, and expertise.29,36 The nature of the constructs and sub-constructs of the 
Process domain are characterized by a similar set of terms.  
Sustainability in pharmacogenomics is particularly important when we consider what 
several participants described as a research-to-clinical progression of the program. Initial internal 
or extramural funding supported many programs with the expectation that the program would be 
self-supporting in the future. The formal implementation programs in pharmacogenomics 
represented by our participants for pharmacogenomics have been leading the way in the clinical 
use of genomic medicine and development of the resources necessary to support the delivery of 
results.19,39 However, most health care institutions in this country do not have robust clinical 
pharmacogenomic programs and current implementers of pharmacogenomics have expressed 
concerns of handoffs outside of their own program.15 The potential ‘down-the-road implications’ 
of pharmacogenomic results on future therapeutic decision making will require that local health 
systems adopt and implement their own programs. They must do this carefully and sustainably 
from the start because most will not have the luxury of robust institutional or extramural support. 
Armed with a deeper understanding of the Process domain and the infrastructure 
capacities necessary to achieve sustainability of the program, future implementers of clinical 
pharmacogenomics now have a list of factors to consider in designing their own programs with 
sustainability at is core. Moreover, they have the ability to avoid some of the roadblocks and 
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challenges these innovators have faced. Future work should examine more closely the economic 
implications of revising an initial implementation plan. Future resource-limited institutions must 
be able to prioritize the initiatives to establish a clinical and operationally effective 
pharmacogenomic program while keeping costs to a minimum.  
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APPENDIX 1. – SEMI-STRUCTURED INTERVIEW GUIDE 
Thank you for taking the time to speak with me today. My name is Nick Keeling and I am the 
principal investigator on this project. I want to inform you that I’ll be recording this interview, 
and that quoted material may be used for a future publication. Your name and the name of your 
organization will always remain confidential. We expect this interview to take approximately 45 
minutes. You may withdraw at any time if you wish. 
You were asked to be a part of this study because of your clinical, research, and implementation 
experience with pharmacogenomics. Please answer these questions as thoroughly as possible. 
We believe that your insights can guide future implementers of pharmacogenomics and lead to 
greater standardization across different care settings. 
Do you have any questions for me before we begin? 
1. To get started, tell me a bit about your general organizational roles: clinical, research, and 
administrative.  
2. Do you know how your organization became involved in using pharmacogenomics in 
routine patient care? When did it begin? 
o Is pharmacogenomics the primary genomic related initiative? Why was 
pharmacogenomics chosen over something else? 
PLANNING 
3. What were the steps involved in getting a plan in place for implementing the 
pharmacogenomics program?* 
o Who was involved in the planning process? 
4. Tell me how it was communicated to clinicians, leadership, research 
5. Was a formal committee put together to direct the implementation of 
pharmacogenomics?* 
o Tell me about its structure. How and when was it was organized? 
ENGAGING 
Formally Appointed Internal Implementation Leaders 
6. Who has led the implementation of the pharmacogenomics program at your organization 
(physicians, pharmacists, others clinical or non-clinical personnel)?* 
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7. Are there certain groups that you wish had been included at the beginning that would 
have made implementation more successful? 
 
 
Opinion Leaders 
7. Who were the key influential individuals (or opinion leaders) to get on board with 
implementing a pharmacogenomics program? 
o To what extent have these individuals influenced others' use of 
pharmacogenomics?  Success of the implementation?  
Champions 
8. Other than formal implementation leadership, what people in your organization have 
taken on the role of a ‘champion’ for pharmacogenomics? 
o How has this supported the implementation? What has been most productive? 
o Who else is needed to ‘champion’ this successfully? 
1. More administrators, advanced practice, genetic counselors? 
Key Stakeholders 
11. What steps have been taken to encourage clinicians to use pharmacogenomics?* 
o What was the most successful way to communicate with or approach them? 
o What types of training were offered to your clinicians? 
Innovation Participants 
12. What has been the communication strategy for getting the word out about 
pharmacogenomics to patients and families?  
o What certain communication processes have worked best? 
External Change Agents 
15. What role, if any, have peers, external organizations, research groups, or individuals 
played in helping execute the pharmacogenomics program at your organization?* 
o How were/are they involved? What kinds of activities were/are they doing? 
EXECUTING 
8. Has your pharmacogenomics program been implemented according to the initial plan? 
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9. Were there aspects of the plan that created difficulties in the implementation of the plan? 
10. What were some of the more significant revisions or refinements to the plan that were 
developed during the implementation process? 
o How were these shared with other key stakeholders?  
REFLECTING & EVALUATING 
16. Were there explicitly set goals you and your team developed in relation to the 
implementation of your pharmacogenomics program?* 
o Were these communicated beforehand? To whom? 
o What goals still remain?  
17. What data are collected/measures tracked to evaluate progress toward the goals?*  
o Are these clinical, economic, or descriptive? 
18. Have you collected structured feedback from clinical staff on their experiences with 
pharmacogenomics?  
o Was it positive? Negative? Neutral? 
o Was this collected with the intent to publish? Or for internal use? 
1. If yes, was this published and in what setting? 
2. If no, what was this rationale? 
19. How have these outcomes been distributed to implementation leaders and other 
appropriate stakeholders? Mode? Frequency? 
o How has this been used to improve practice?  
20. What experience has made the biggest impact in improving the delivery of 
pharmacogenomics? 
That is all the specific questions I have for you today. Is there anything else you would like to 
add to our discussion? Feel free to be as broad or detailed as you’d like.  
Thank you so very much for your time. 
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APPENDIX 2. – INVITATION EMAIL FOR SURVEY AND INTERVIEW 
  
Good Morning, 
  
This is an invitation to participate in ongoing academic research focused on the implementation 
and sustainability of pharmacogenomics. (If the potential respondent was nominated through 
snowball sampling the following sentence will be added: “You were nominated by ______ as an 
appropriate person to participate in this research.)  
This research includes a 5 minute survey and telephone interview expected to last around 45 
minutes. The interviews will take place between XXX and XXX. The interviews will be 
recorded, but your name and organization will remain confidential. We do not believe there are 
any risks associated with this research. You do not have to take part in this study and you may 
stop participating at any time. 
Please click the link just below to complete the survey. Your responses to this survey will not 
affect your eligibility to participate in the interview.  
<<<Qualtrics link>>> 
 
Please fill out this confidential Doodle poll with your preferred time for the interview.  
<<<Doodle poll link>>> 
 
Please contact Nick Keeling at nick.keeling@stjude.org if you have any questions. Nick will 
reach out to you with a calendar invite at one of your available times. 
As a reminder, this study has been approved by The University of Mississippi’s Institutional 
Review Board (IRB).  If you have any questions, concerns, or reports regarding your rights as a 
participant of research, please contact the IRB at (662) 915-7482 or irb@olemiss.edu. 
I have read and understand the above information. By completing the survey and interview I 
consent to participate in the study. 
Thank you very much for your time. 
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APPENDIX 3. – ONLINE DEMOGRAPHIC SURVEY 
Thank you for your participation in this research. Responding to this survey serves as your 
consent to participate. Please answer all the questions. Your name and organization will always 
remain confidential. 
1. Are you at least 18 years of age or older? 
o Yes 
o No (not eligible to continue) 
2. Are you a...? 
o Physician (MD or DO) 
o Pharmacist (PharmD or RPh) 
o Clinical research scientist (PhD) 
o Other, please specify ________________ 
3. Are you at an academic institution? 
o Yes 
o No  
4. Please select any pharmacogenomic research groups/networks/consortiums you are either 
involved with or a member of (select all that apply) 
o CPIC 
o IGNITE 
o eMERGE 
o PGRN 
o PharmVar 
o Other, please specify ___________ 
5. How long has your institution been implementing pharmacogenomics into clinical 
service? 
o Less than 1 year 
o 1 – 3 years 
o 3 – 5 years 
o More than 5 years 
      
6. How many germline variants do you currently have in clinical service? 
            _________variants 
 
7. Please select the type(s) of clinical pharmacogenomic testing your institution conducts               
(select all that apply) 
o Single-gene genotyping 
o Multi-gene genotyping 
o Exome sequencing for pharmacogenes 
o Genome sequencing for pharmacogenes 
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8. Is most of your clinical pharmacogenomic testing done… 
o Preemptively 
o Reactively 
o Both 
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APPENDIX 4. – EMAIL TO ASSIST IN SNOWBALL SAMPLING 
  
Good Morning, 
  
Thank you again for participating in the recent interview on pharmacogenomic implementation. 
We are reaching out to you again today to ask you to nominate one or more additional potential 
respondents to complete the same interview. You are under no obligation to nominate additional 
participants and your choice has no bearing on your previous response. 
 
Please respond to this email with the name, credential, professional job title, and best contact 
email for your nominated respondent(s).  
By responding to this email with your nominations you are also consenting for us to reveal your 
name to your nominee(s). 
 
Please contact Nick Keeling at nick.keeling@stjude.org with any questions. 
 
As a reminder, this study has been approved by The University of Mississippi’s Institutional 
Review Board (IRB).  If you have any questions, concerns, or reports regarding your rights as a 
participant of research, please contact the IRB at (662) 915-7482 or irb@olemiss.edu. 
 
Thank you very much for your time. 
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SECTION III. 
 
SUSTAINABLE DELIVERY OF PHARMACOGENOMICS IN                   
PRIMARY CARE: TESTING THE POTENTIAL FOR PHYSICIAN-
PHARMACIST COLLABORATION 
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1.  BACKGROUND 
Implementation programs for pharmacogenomics, and studies of genetic variation and its 
influence on drug response, continue to increase in number and public funding.1 As barriers are 
overcome, the most challenging obstacles to the continued success of this field of study become 
clearer. Two such obstacles preventing broader use of “clinical pharmacogenomics”, a term used 
to reflect its application in clinical practice, are provider knowledge/education and testing 
reimbursement by insurers.2-6 In fact, the Implementing Genomics into Practice (IGNITE) 
Sustainability Working Group recently identified the need for expanded (pharmaco)genomic 
education for providers as the most important construct for the sustainability of the science.5  
The noted insufficiencies in provider knowledge about pharmacogenomics and 
preparedness to use these results reaches back several years and stubbornly persist.7-10 Studies 
from 2012 found that although nearly all (98%) of physicians believed the patient’s genetic 
profile influences their response to drug therapy, 90% felt inadequately informed on testing 
availability and application, and approximately 80% of primary care physicians (PCPs) had 
never ordered a pharmacogenomic test.7,11 More recent work shows limited progress in the 
number of tests ordered, with around 30% of physicians reporting having ordered or 
recommended a pharmacogenomic test in the past six months.9 Despite this improvement, family 
physicians, a first touch-point for many patients, still have a lower likelihood of adopting 
pharmacogenomics.9 This compounds concerns from physicians based in academic settings, 
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actively engaged pharmacogenomic implementation, around patient hand-offs to providers 
outside of these institutionally based pharmacogenomics implementation programs.12  
Despite some of these shortcomings, physicians from pharmacogenomic programs within 
the IGNITE network are reporting improvements in adequate training and confidence regarding 
the use of pharmacogenomics.10 Physician attitudes on the clinical usefulness, training and 
preparedness, and awareness of resources were all statistically significantly more positive for 
pharmacogenomics as compared to disease genetics.10 Being able to find and use reliable sources 
of information to understand and communicate risk also had higher reported odds for 
pharmacogenomics compared to disease genetics.10 However, confidence in the ability to use 
pharmacogenomic results remained low with 30% of physicians responding as such.10  
Parallel research with pharmacists has demonstrated a pharmacogenomic education need 
for these providers as well. While nearly all pharmacists had positive attitudes toward 
pharmacogenomics, and more than half (57%) believe it is their role counsel patients on this 
information, less than 20% feel their training had been adequate to deliver this information.13 
Early assessments of pharmacists as providers of pharmacogenomics found that 85% felt they 
should be knowledgeable and 65% said they should be capable of providing information on 
appropriate use of testing.14  
The pharmacy profession has also taken lead in the education of providers through 
pharmacogenomics curriculum development and continuing education programs.15-17 
Researchers from the Mayo Clinic shared their approaches to achieving competencies in 
pharmacogenomics for healthcare professionals. In particular, they highlighted their work with 
educating pharmacists, the unmet need to craft “genomic nurses”, and the overall importance of 
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transdisciplinary care in this field.18 Successful pharmacogenomics implementation programs at 
academic health systems have been delivered in a highly collaborative infrastructure, several of 
which have been led by senior pharmacists.4,19,20 Additionally, two of the largest professional 
pharmacy organizations, the American Society of Health-System Pharmacists (ASHP) and the 
American Pharmacists Association (APhA), have both put out official positions and statements 
in the past decade on the role of the pharmacist in the delivery of pharmacogenomics.21,22 
Specifically, they highlight the unique skills and abilities of pharmacists, their relation to the 
delivery of pharmacogenomics, opportunities for integration into medication therapy 
management (MTM) services, and call on the educational community to prepare pharmacists to 
apply pharmacogenomic information to therapeutic decision-making. 
Pharmacist-physician collaboration in pharmacogenomics 
Pharmacists possess a clinical skill set complementary to the delivery of 
pharmacogenomics with their specialized training in the pharmacokinetics and dynamics of 
medications, their interactions, and dosing, all of which can be applied to reduce adverse events 
driven by drug-gene interactions.23 The noted successes of institutional pharmacogenomic 
programs led by senior pharmacists has resulted in recent calls to study the role of the pharmacist 
as the local ‘clinical champion’ in greater detail.24  
Collaborative practice agreements (CPAs) or collaborative drug therapy management 
programs (CDTMs) between physicians and pharmacists may be one way to improve the 
delivery of pharmacogenomics through a transdisciplinary structure in primary care, and to 
address those constructs most important to the sustainability of genomic medicine.: expanding 
provider education and improving the integration of genomic information into workflow.5 CPAs 
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and CDTMs expand pharmacists’ involvement in patient care by providing a defined protocol 
under which pharmacists may complete assessments, provide counseling, order diagnostic tests, 
and manage the patient’s drug regimen.25 It is important to recognize that legislation pertaining 
to CPAs and CDTMs differs from state to state. Pharmacists may enter into formal collaborative 
practice agreements in 48 states and the District of Columbia.26 Of these states, 38 allow 
pharmacists to initiate drug therapy and 45 allow them to modify an existing therapy. These 
allowances must be explicitly stated in the agreement, and in 29 states there is a requirement to 
specify which medications or disease states the pharmacist can manage. Additionally, 31 states 
currently allow the pharmacist to order and interpret laboratory tests, which could include 
pharmacogenomics.26   
A meta-analysis of US pharmacists’ involvement in a patient care team found significant 
improvements in both therapeutic, safety, and humanistic outcomes over comparative services.27 
Recent studies with physicians in active supervisory roles of a clinical pharmacist in a CPA have 
reported better clinical outcomes, more efficient medication management, clinically helpful 
recommendations, improved efficiencies in care, and an advanced learning environment which 
includes newly accessible drug knowledge.28,29 Limited reimbursement and billing 
considerations are the most frequently reported barriers; as well as worries over a loss of control 
and confidence in the pharmacists’ clinical.29,30 Under four percent of responding primary care 
physicians indicated they would not be accepting of clinical pharmacist practitioners.29 However, 
previous literature has shown that 25% of pharmacists feel that acceptance by primary care 
physicians is a barrier to collaborative practice.  
Family physicians and community pharmacists in Canada, a country where the traditional 
function of a pharmacist more closely mirrors the CPA function of US pharmacists, also report 
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contrasting perceptions of importance in the function of community pharmacists.31 There was 
44% agreement for the pharmacist function “providing advice regarding drug interactions” and 
25% for both “assisting in medication dosage adjustment” and “providing drug information to 
help select a medication”, suggesting there remains space for imporvement.31 Economic analyses 
of pharmacist-physician collaborations have also reported positive (cost-saving) findings in 
addition to clinical improvements across various scenarios.32,33  
The role and responsibilities of the pharmacist in the delivery of clinical 
pharmacogenomics has been also been examined. A prospectively designed pilot study measured 
the clinical support of two different pharmacist models (in-house vs. on-call) at two primary care 
clinics.34 A pre-test assessment among the primary care physicians showed that over 90% felt 
having assistance in interpretation of pharmacogenomic results would increase the likelihood of 
them ordering a test. Eighty-nine percent thought that the pharmacist or the geneticist/genetic 
counselor would have “some or a large role in delivery pharmacogenomic testing”.34 Results 
from the pilot study also showed that the physical presence of a pharmacist enhanced the pre-
held perspectives.34 Interestingly, when the ‘continued test utilization’ was assessed, one-third of 
providers reported that they were ‘very or somewhat likely’ to continue ordering. However, 
when the pharmacist was removed from the clinic there were no new pharmacogenomic tests 
ordered.34 This illuminates the role that the pharmacist has in the sustainment of 
pharmacogenomic test ordering.  
Pharmacist appear well-positioned to assist in the clinical delivery of pharmacogenomics. 
The positive outcomes of using pharmacists in primary care teams, success of pharmacist-led 
pharmacogenomic implementation programs, a pharmacy profession leading new educational 
initiatives in pharmacogenomics, and a scope of practice in many states enabling pharmacist 
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involvement in pharmacogenomics provide support for this statement.35 Although most 
physicians perceive collaborating with a pharmacist as being beneficial to their practice and 
patients, there is little consensus from physicians, and a need for further study, on the level of 
clinical responsibility they should have, including the pharmacist role in the delivery of clinical 
pharmacogenomics. 
Designing the implementation and delivery of pharmacogenomics in the primary care 
setting could benefit from similar collaborative infrastructures as those outlined in the pilot 
studies. The challenge before the pharmacogenomics community will be to design these 
implementations with a solid understanding of the factors impacting its longer-term 
sustainability. As such the objective of this study is to understand how primary care physicians 
currently view the use of pharmacogenomics in practice and how clinical collaboration with 
pharmacists may influence their perspective.  
Implementation science and study hypotheses 
Previous research has provided the field of implementation science, the study of methods 
to improve the adoption of evidence-based research and practice, with a “working taxonomy” of 
eight outcomes to use when evaluating successful implementation.36,37  Three of these outcomes: 
acceptability, appropriateness, and feasibility, were recently developed into measures with their 
psychometric properties having been assessed.38  
• Acceptability is “personal”: individual judgments of ‘clinical pharmacogenomics’ based 
on differing needs, preferences or expectations.37  
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• Appropriateness is “technical or social”: judgments based on the efficacy of the ‘clinical 
pharmacogenomics’ achieving some purpose under certain conditions (type of patient, 
culture, infrastructure, etc).37,38 
• Feasibility is “practical”: judgments based on the perceived ease of implementing 
‘clinical pharmacogenomics’ given the individual’s necessary resources (effort, time, or 
money) and unique circumstances.37,38 
The three measures of these implementation outcomes are the Acceptability of Intervention 
Measure (AIM), the Intervention Appropriateness Measure (IAM), and the Feasibility of 
Intervention Measure (FIM).38 High scores on these outcome measures provide researchers an 
early indication of the likelihood that staff will adopt a new ‘something’, or if more work is 
needed to increase scores in one or more outcome measures. Standardizing the use of 
implementation outcomes has been seen as a critical step for conceptualizing and evaluating the 
success of a new intervention.39 The outcomes serve as both indicators of a successful 
implementation and intermediate outcomes related to the eventual clinical, economic, or social 
outcomes. Without a successful implementation, the intervention or treatment is likely to be 
ineffective.39 To make clinical pharmacogenomics effective to patients, we must ensure the 
providers delivering the intervention are doing so in such a manner to facilitate its success. 
Further, these standardized measures make future meta-analyses on this subject possible.  
 Using these measures, we aimed to collect primary care physicians’ (PCPs) current opinions 
on the acceptability, appropriateness, and feasibility of pharmacogenomics in their primary care 
practice. An exploratory analysis was conducted to identify what demographic variables were 
significant predictors of the baseline AIM, IAM, and FIM scores. As the central analysis herein, 
we aimed to test the appropriateness and feasibility of delivering of clinical pharmacogenomics 
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across experimentally manipulated scenarios that reflect realistic, potential variations in the roles 
of physicians and pharmacists. The following research questions and hypotheses were tested: 
Research question 1: What level of pharmacist involvement in the functions of delivering 
clinical pharmacogenomics do primary care physicians find most appropriate? 
Hypothesis 1. The appropriateness of clinical pharmacogenomics will be positively associated 
with greater levels of pharmacist involvement and collaboration. 
Hypothesis 1a. PCPs will consider clinical pharmacogenomics more appropriate when the 
pharmacist is located in the clinic. 
Hypothesis 1b. PCPs will consider clinical pharmacogenomics more appropriate when the 
pharmacist selects and orders the pharmacogenomic test. 
Hypothesis 1c. PCPs will consider clinical pharmacogenomics less appropriate when the 
pharmacist modifies the medication regimen and counsels the patient. 
Research question 2: What level of pharmacist involvement in the functions of delivering 
clinical pharmacogenomics do primary care physicians find most feasible? 
Hypothesis 2. The feasibility of clinical pharmacogenomics will be positively associated with 
greater levels of pharmacist involvement and collaboration. 
Hypothesis 2a. PCPs will consider clinical pharmacogenomics more feasible when the 
pharmacist is located in the clinic. 
Hypothesis 2b. PCPs will consider clinical pharmacogenomics more feasible when the 
pharmacist selects and orders the pharmacogenomic test. 
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Hypothesis 2c. PCPs will consider clinical pharmacogenomics more feasible when the 
pharmacist modifies the medication regimen and counsels the patient. 
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2.  METHODS 
Study design 
This study used a quantitative survey methodology that included a series of experimental 
vignettes. Experimental vignette surveys typically consist of short narrative scenarios or lists of 
attributes manipulated via the included levels. This allows the researcher to exert a level of 
experimental control, excluding variables that might confound results, and establish causal 
relationships if they exist.40 Incorporating vignettes has been shown to be a practical 
methodology for the assessment of clinical practice scenarios.41  
Survey instrument 
The survey consisted of two main sections: the first captured participant demographics, 
practice characteristics, data on the respondent’s practice integration with pharmacists and 
familiarity with collaborative practice, and the respondent’s experiences and perspectives on 
clinical pharmacogenomics. The second was the experimental vignette portion which will be 
described in more detail below. 
 Several practice characteristic questions were adapted from a survey instrument 
developed by the National Cancer Institute for evaluation of primary care physician 
recommendations and practice for cancer screening.42 Changes made included the altering the 
type of response (multiple choice vs. open response) or decreasing number of multiple-choice 
options available to the respondent. Three items to assess perceived knowledge of 
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pharmacogenomics in this section come from the IGNITE Common Measures Working Group 
“Provider Baseline Knowledge of Genetic Testing Survey” and are available online in the 
IGNITE Spark Toolbox.43  These items were chosen so that a comparison of respondents 
perceived knowledge of using pharmacogenomics could be made to their awareness of the 
leading pharmacogenomic resources such as the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) and the Pharmacogenomics Knowledgebase (PharmGKB). Also, a baseline 
assessment of ‘acceptability’, ‘appropriateness’, and ‘feasibility’ of clinical pharmacogenomics 
was measured using the AIM, IAM, and FIM scales. The term ‘clinical pharmacogenomics’ 
replaced the word “intervention” in the author’s original scales.38 For the IAM and FIM scales, 
the language ‘in my primary care practice’ was added. The authors explicitly state in the 
psychometric study that the items were made as “general as possible” to facilitate adaptation to 
specific contexts or clinical problems.38 Each item is measured using a 5-point Likert-type 
response format and scores were created by averaging responses for all items in each scale.  
Independent variables 
The vignette portion of the survey was a 2 x 2 x 2 between-subjects experimental design. 
Table 1 describes the levels of the factors in more detail. 
Table 1. Experimental vignette manipulations 
Factors # of levels Description of levels 
Pharmacist location 2 (b/w) 
• In the clinic 
• Outside the clinic 
Selects and orders pharmacogenomic 
test 
2 (b/w) 
• Pharmacist 
• Physician 
Manages results and modifies the 
patient’s medication regimen 
2 (b/w) 
• Pharmacist 
• Physician 
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The factor ‘pharmacist location’ mirrors the two pharmacist arms of the Haga et al. trial 
discussed previously.34 The remaining factors represent the varying responsibilities a pharmacist 
might have with the delivery of pharmacogenomic testing in a collaborative practice 
environment. These include the responsibilities of selecting and ordering the test and the 
subsequent management and use of the results for modification of drug therapy. Table 3 shows 
each factor and its corresponding levels, as well as a description of the levels. The survey was 
pre-tested with two primary care physicians reflective of our target sample and slight revisions to 
clarify the language in the vignettes were made based on this feedback. The exact language of 
the vignettes can be found at the end of Appendix 1. 
Dependent variables 
The outcome measurement following the experimental vignettes was a reassessment of 
the IAM and FIM scales with the language “delivered this way” inserted into the original 
measure to better reflect the information presented in the vignettes. Only the IAM and FIM were 
selected for measurement following the vignettes because the aforementioned ‘criterion’ 
descriptions of these two scales better capture the objective to understand the potential for 
collaborative practice in the delivery of clinical pharmacogenomics. The same adaptation to 
measures described previously was maintained in the reassessment to reinforce the focus on the 
appropriateness and feasibility of clinical pharmacogenomics to their practice broadly. The AIM 
scale was excluded from the vignette because the language of the items was not sensical given 
the objective and focus on collaborative practice environments. 
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Data collection and sampling methods 
 A power analysis indicated that to achieve a power of at least 0.90 to detect medium main 
and interaction effects with a significance level of 0.05, a total of 176 respondents were needed. 
Given our 2x2x2 design, this required 22 cases for each of the eight treatment groups. To 
facilitate this data collection, Reckner Healthcare (Chalfont, PA) was engaged to recruit a sample 
of primary care physicians (family medicine or internal medicine) from their available panel. An 
invitation email consistent with Reckner Healthcare’s policies was distributed to eligible primary 
care physicians on their panel. These physicians were not offered any incentive but were 
provided with a summary of the results upon analysis (APPENDIX 2). Participants were 
randomly assigned to one of the eight treatment groups upon beginning the survey and data 
collection continued until the required 22 cases per group was achieved.  
Analysis procedure 
A descriptive analysis provided data on general and pharmacist-related practice 
characteristics, as well as mean scores on the AIM, IAM, and FIM scales prior to any 
manipulation. Scale values on these three outcomes range from 1 to 5, have been treated as 
continuous variables for analysis, and averaged for a single score. Higher scores indicate greater 
levels of acceptability, appropriateness, or feasibility.  Three separate multiple regressions were 
used to assess if there were significant predictors of the baseline mean scores of the AIM, IAM, 
and FIM without experimental manipulations. Predictors included questions related to the 
importance of pharmacists in clinical care, perceived pharmacogenomic knowledge as measured 
by the three items from the IGNITE Spark Toolbox, and the average score across the familiarity 
with CPIC and PharmGKB. These predictors were included because of their association with 
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provider education and pharmacist collaboration. To test the effect of the independent variables 
on the scores for the IAM and FIM scales after vignette manipulation, the data were analyzed 
using a three-way analysis of variance (ANOVA) procedure for each of the two dependent 
variables. All tests were conducted at the α=0.05 level of significance. 
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3.  RESULTS 
 The number of respondents to achieve our desired power and to satisfy equal 
stratification across our eight groups was achieved with a final sample of 177 family practice or 
internal medicine physicians. Data collection was closed as soon as 22 respondents were 
collected for each group. One group or vignette received an extra respondent likely due to 
another respondent starting the survey and finishing later. This extra respondent was excluded 
from any analysis.  
Nearly two-thirds of respondents were family medicine physicians and close to 90% 
having practiced more than 16 years. Most were either practice owners or associates and worked 
in practices with 30 or fewer physicians. About a third of respondents worked in multi-specialty 
clinics. On average, physicians reported that collaborating with a pharmacist in their primary 
care practice fell between somewhat and moderately important (3.47 on a 5-point Likert-type 
item). Physician familiarity with CPAs scored between slightly and somewhat (2.5 out of 5). Just 
over three-quarters of physicians indicated that they only interact with a community pharmacist, 
the remaining responded that they had a full-time or part-time pharmacist that worked in the 
clinic. Fifteen percent of physicians indicated that pharmacist involvement was part of a formal 
CPA. Of those involved in a formal CPA,  85% granted the pharmacist full access to patient’s 
medical records. 
Several questions were asked related to the physician’s exposure and experience with 
pharmacogenomic testing in their practice and revealed some interesting findings. Familiarity 
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with using pharmacogenomic information scored between slightly and somewhat familiar (2.63 
out of 5). On the three items from the IGNITE Spark Toolbox scores were slightly higher than 
overall familiarity, ranging from 2.96 on the “my training has prepared me to treat patients 
whose genetics place them at high risk for medical conditions” item and a 3.18 on the “I am 
confident in my ability to use the results of a pharmacogenomic test” item as well as the I can 
find/use reliable sources of the information I need to apply pharmacogenomic testing while 
caring for patients” item.43   Scores on the items assessing familiarity with Clinical 
Pharmacogenetics Implementation Consortium (CPIC) and Pharmacogenomics Knowledgebase 
(PharmGKB) were much lower, 1.61 and 1.59, respectively. Most respondents (66%) have never 
had a patient ask about pharmacogenomics and just over half had never used pharmacogenomic 
information in patient care. Insurance coverage and reimbursement remain top barriers to more 
widespread use. Close to 80% of physicians indicated that removing selection and ordering of 
the test from clinical workflow would make delivery more feasible. Appendix 3 contains 
complete tables of respondent demographics and practice characteristics.   
Baseline assessment of the implementation outcomes from Weiner et al., acceptability 
(AIM), appropriateness (IAM), and feasibility (FIM) scales, are provided below in Table 2.38 
Scores on the AIM were the highest across the three with a slight drop on the IAM scale, and a 
further drop on the FIM. Only the last item in the FIM scale scored, on average, below a 3 on a 
5-point Likert-item.  
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Table 2. Implementation Outcome Measures Applied to 
Clinical Pharmacogenomics  
(1 = Strongly disagree, 5 = Strongly Agree) 
Mean 
Acceptability of Intervention Measure (AIM)  
Clinical pharmacogenomics meets my approval 3.72 
Clinical pharmacogenomics is appealing to me 3.77 
I like clinical pharmacogenomics 3.62 
I welcome clinical pharmacogenomics 3.73 
Overall Mean = 3.71  
Intervention Appropriateness Measure (IAM)  
Clinical pharmacogenomics seems fitting in my primary care 
practice 
3.45 
Clinical pharmacogenomics seems suitable for my primary care 
practice 3.48 
Clinical pharmacogenomics seems applicable to my primary care 
practice 3.60 
Clinical pharmacogenomics seems like a good match for my 
primary care practice 3.49 
Overall Mean = 3.50 
Feasibility of Intervention Measure (FIM)  
Clinical pharmacogenomics seems implementable in my primary 
care practice 3.19 
Clinical pharmacogenomics seems possible for my primary care 
practice 3.54 
Clinical pharmacogenomics seems doable in my primary care 
practice 3.36 
Clinical pharmacogenomics seems easy to use at my primary care 
practice 2.99 
Overall Mean = 3.27 
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The ANOVA results from the experimental vignette manipulation can be seen in Table 3. 
Recall, only the IAM and FIM scales were used as the dependent variables following the 
vignettes. 
Table 3. ANOVA Results for Dependent variables (n=176) 
 Dependent Variables 
Independent variables 
Intervention 
Appropriateness 
F ratio (p value)       
Intervention        
Feasibility 
F ratio (p value)   
Main effects 
   Location of pharmacist 
   Provider selecting and ordering test 
  
1.132 (0.289) 0.947 (0.332) 
2.310 (0.130) 3.004 (0.085) 
   Provider managing results and modify  drug 
therapy 
0.59 (0.808) 0.008 (0.927) 
Two-way interactions 
   Location * Select-order 
   Location * Manage-modify 
   Select-order * Manage-modify 
  
2.897 (0.091) 1.069 (0.303) 
4.272 (0.040)* 2.900 (0.090) 
1.265 (0.262) 0.408 (0.524) 
Three-way interaction 
   Location * select-order * manage-modify 
  
0.075 (0.785) 0.092 (0.761) 
* Significant at p < 0.05                                                                                         
  
There were no significant main effects, as well as no significant second-order interactions. 
However, there was a significant first-order interaction between the location of the pharmacist 
and the provider responsible for managing and modifying drug therapy. This was only significant 
for the IAM scale dependent variable (F = 4.272, P = 0.040). Figure 1 below shows the plot of 
this cross-over interaction. A simple effects analysis shows that if the pharmacist is managing 
and modifying drug therapy their physical location does make a statistically significant 
difference (F = 4.829, p = 0.029). If the physician is responsible for managing and modifying, 
the location of the pharmacist does not make statistically significant difference (F = 0.492, p = 
0.482). 
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Figure 1. Two-way interaction of Location * manage-modify on appropriateness (IAM) scores 
 Although not significant at α = 0.05, two other potential cross-over interactions were 
observed. The interaction effect of location of the pharmacist and the person responsible for the 
selecting and ordering of the pharmacogenomic test on the IAM dependent variable was non-
significant (F = 2.897, P= 0.091). The plot of this interaction can be seen in Figure 2. A similar 
pattern emerges in this simple effects analysis as the previous one.  If the pharmacist is 
responsible for selecting and ordering, the location of the pharmacist did make a difference in the 
appropriateness according to PCPs (F = 3.789, p = 0.053). 
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Figure 2. Two-way interaction of location * select-order on appropriateness (IAM) scores 
 Another potential crossover interaction was observed between location and the persons 
responsible for managing the test results and modifying therapy, but this time for the FIM scale 
dependent variable (F = 2.900 P = 0.090). The plot for this interaction is shown in Figure 3. 
Again, the simple effects analysis showed a similar trend although not as strong as the two 
previous ones. If the pharmacist was responsible for managing and modifying, their location in 
the clinic seems to have an impact on the feasibility of delivering pharmacogenomics to the 
responding PCPs ((F = 3.569, p = 0.061)  
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Figure 3. Two-way interaction of location * manage-modify on feasibility (FIM) scores 
 
As such, both Hypothesis 1 and Hypothesis 2 are not supported. However, as shown 
earlier, the presence of a statistically significant first-order interaction term changes our 
interpretation of the main effects associated with Hypothesis 1a and 1c. All three hypotheses, 1a 
– 1c, are not supported based solely on the main effects. All three sub-hypotheses from 
Hypothesis 2 are also not supported based on their main effects. Although there was no 
statistically significant first-order interaction terms for this outcome variable, the potential for 
cross-over interactions on the basis of the cell means plots were observed and suggest that PCPs 
do find delivering pharmacogenomics more feasible when the pharmacist is located in the clinic 
and is responsible for managing and modifying drug therapy.   
All three regression models with the baseline AIM, IAM, and FIM scores as dependent 
variables were significant (P < 0.001). Their respective R2 values can be found in Table 4 along 
with the full model results. With the baseline scores on the three implementation outcome scales 
136 
 
serving as our dependent variables, the same three independent variables were significant across 
the three models. These included an item measuring the importance of collaborating with a 
pharmacist in the responding physician’s practice, as well as the perceived pharmacogenomic 
knowledge and familiarity with pharmacogenomic resources variables. The only non-significant 
variable included was actual pharmacist involvement in the primary care practice of the 
responding physician. This was non-significant across all three models.  
Table 4. Regression results of pharmacist and pharmacogenomic influences 
on baseline AIM, IAM, FIM scores (n=176) 
 
 AIM 
(R2 = 0.317) 
F ratio (P value) 
IAM 
(R2 = 0.381) 
F ratio (P value) 
FIM 
(R2 = 0.469) 
F ratio (P 
value) 
Importance of collaborating with a 
pharmacist in the primary care 
practice 
0.289 (<0.0001*) 0.348 (<0.0001*) 
0.298 
(<0.0001*) 
Pharmacist involvement in primary 
care practicea 
  
 
    Full-time in the clinic 0.060 (0.397) 0.025 (0.711) 0.027 (0.664) 
    Part-time in the clinic 0.033 (0.623) 0.103 (0.104) 0.067 (0.256) 
Perceived PGx knowledgeb 0.270 (<0.0001)* 0.292 (<0.0001*) 
0.346 
(<0.00001*) 
Familiarity with PGx resourcesc 0.163 (0.030)* 0.150 (0.036*) 
0.251 
(<0.0002*) 
 std β (p value) 
a Dummy variables: reference group is working with a community pharmacist only 
b Average score across the three items included from the IGNITE Spark Toolbox 
c Average score across familiarity with CPIC and PharmGKB questions 
* Significant at p < 0.05                                                                                         
 
   
 
 
137 
 
 
 
 
 
 
4. DISCUSSION 
 The focal analysis of this study showed that when a pharmacist responsible for managing 
pharmacogenomic results and modifying drug therapy, primary care physicians found this to be 
significantly more appropriate when the pharmacist was physically located in the clinic with the 
physician. If the pharmacist was also selecting and ordering a pharmacogenomic test, the PCPs 
find this to be more appropriate when the pharmacist was located in the clinic as well, as 
opposed to being in the community. This IAM score was nearly identical to the average score 
when the physician was responsible for selecting and ordering with a pharmacist in the clinic. 
These results seem to indicate that the physical presence of a pharmacist is driving physician 
perceptions of how appropriate delivery of clinical pharmacogenomics is to their primary care 
practice.  
  Regarding the feasibility outcome, when the pharmacist was responsible for managing 
results and modifying drug therapy, PCPs found this to be more feasible when the pharmacist 
was located in the clinic. Interestingly, the “pharmacist in the clinic” cell mean differences were 
identical for this interaction term on both the IAM and FIM scales, with similar overall mean 
scores. The absence of significance for feasibility may be due to a smaller cell mean difference in 
the “in the community” scenario. However, it is important to note the similarities between the 
scores for the appropriateness and feasibility of delivering pharmacogenomics when a 
pharmacist is physically located in the clinic and is responsible for managing and modifying the 
drug regimen. Additional investigations of this potential relationship would be needed to confirm 
this trend.  
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 Results from this study indicate that physicians may be willing to sacrifice some clinical 
decision-making autonomy when dealing with the delivering of pharmacogenomics. The positive 
results regarding appropriateness of an in-clinic pharmacist handling the management of test 
results and modification of drug therapy is particularly illuminating. The responsibility of 
modifying drug therapy is currently the highest levels of clinical practice a pharmacist is allowed 
to engage in under a CPA.25,26 These results may be indicative of a larger theme in the literature 
that primary care physicians lack understanding of pharmacogenomics and may be willing to 
defer to pharmacists if physical oversight remains possible.7 
Additional results from the study may provide evidence for why physicians were willing 
to relinquish some autonomy for the delivery of clinical pharmacogenomics. Results on the “Pre-
implementation Provider” items from the IGNITE Spark Toolbox all hovered around the mid-
point on the agree/disagree Likert-type item. Scores on the general familiarity with 
pharmacogenomic question were somewhat lower than the IGNITE items, but more interesting 
was the drastically lower scores regarding primary care physician familiarity with CPIC and 
PharmaGKB. More research should be done to reveal where physicians are currently getting this 
type of information from if not CPIC or PharmGKB, and what can be done to increase awareness 
and use of these resources.  
 The results from the three regression models revealed several strong predictors of scores 
on the baseline assessment of the AIM, IAM, and FIM scales. The reported importance of 
collaborating with a pharmacist and perceived PGx knowledge demonstrated a stronger effect on 
the dependent variable than the familiarity with PGx resources. This positive relationship 
between pharmacist collaboration and scores on the acceptability, appropriateness, and feasibility 
of clinical pharmacogenomics seems to be in line with the findings from the vignettes. Although 
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we did not have significant main effects in that analysis, these additional regression results, taken 
together with the interactions noted previously, show that physicians value the contribution of a 
pharmacist when delivering clinical pharmacogenomics in primary care.   
The findings from this current study are also consistent with the previous work that is 
available. The two-arm pilot study discussed earlier reported a significantly higher number of 
pharmacogenomic tests ordered when a pharmacist was located in-house, as well as an increase 
in the number of pharmacist consultations.34 The pre-pilot survey found that most physicians 
already believed either pharmacists or geneticists/genetic counselors were likely to have a role in 
this clinical delivery.34 Others have proposed that these two types of non-physician providers can 
play complementary roles in the effective delivery of pharmacogenomics.23,44  
It is important to consider the implications of this study in light of how prepared the 
pharmacist is to take on these additional responsibilities. Pharmacists have generally positive 
attitudes toward their role in delivering pharmacogenomics, have been instrumental in the 
development of research-based implementations of clinical pharmacogenomics in the US and 
abroad, and are continuing to lead efforts in clinical education of pharmacogenomics.13,17,19 Also, 
ongoing research is contributing to our understanding of how feasible it is for pharmacists to be 
the ones delivering this information.45-47 These studies show that pharmacists are making correct 
interpretations of test results close to 90% of the time, consultations were timely and patients 
understand the information, as well as there being high rates of adherence to pharmacist 
recommendations by patients. 
There remains limited literature available addressing the issue of physician-pharmacist 
collaboration in primary care specific to clinical pharmacogenomics. However, this is of great 
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importance as patients are becoming increasing interested and aware of genomic testing and  
pharmacogenomics.48 An in-depth qualitative assessment of patient perceptions to genomic 
testing revealed that patients believe that pharmacogenomics could be helpful in identifying 
problematic prescriptions and used to inform future prescribing.48 However, concerns around 
insurance coverage and who should have access to the information were noted. While patients 
felt the pharmacist could effectively use the pharmacogenomic data, some thought this 
interaction was redundant while others rely solely on their physician for medication 
information.49 
The findings of this current study support the idea that pharmacists co-located with 
physicians may be effective collaborators in the delivery of clinical pharmacogenomics and 
extend our understanding of how appropriate and feasible this scenario is to  primary care 
physicians.  
Limitations 
 This study was hypothetical in nature and asked physicians to imagine themselves 
essentially engaged in a collaborative practice agreement with a pharmacist. Since familiarity 
with collaborative practice agreements was relatively low and few respondents were engaged in 
such an arrangement, external validity of the relationships shown herein should be externally 
validated in future studies with non-collaborative control groups. About half of the responding 
physicians had never ordered a pharmacogenomic test and may have also biased the responses. 
Another limitation in our manipulation may stem from the fact that we did not perform any 
manipulation checks on the manipulations themselves. This could have led to poor manipulation 
performance and thus the loss of an effect that may have otherwise been there. However, the 
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manipulations were piloted with two primary care physicians before distribution. Their 
comments indicated that they understood the differences in the various scenarios.  
Conclusion 
 When a pharmacist is responsible for managing and modifying drug therapy based on 
pharmacogenomic results, primary care physicians find this more appropriate for their practice 
when the pharmacist is located in the clinic. Physicians also responded that this same scenario 
would likely be more feasible. There is also evidence that it is more appropriate for the 
pharmacist to be located in the clinic if they are also responsible for selecting and ordering a 
pharmacogenomic test.  
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APPENDIX 1. – SURVEY INSTRUMENT 
Welcome and thank you! You are being asked to volunteer for this research study. It is up to you 
whether you choose to participate or not. There will be no penalty or loss of benefits to which 
you are otherwise entitled if you choose not to participate or discontinue participation. You will 
be required to answer each question. As a reminder, this study has been IRB approved and we do 
not believe there are any risks associated with this survey.  
By now you will have read both the invitation email and the information above. By continuing to 
the next page you verify that you are at least 18 years of age and give your consent to participate 
in this study. 
NEXT PAGE 
Part A. Practice and Other Characteristics 
The questions in this section will help us better understand you and your current medical 
practice. 
1. What is your primary medical specialty (i.e., the practice specialty where you spend the 
most hours per week)? 
A. Family Medicine 
B. General Internal Medicine 
C. Pediatrics 
D. Psychiatry 
E. Other 
IF C, D, or E SELECTED IN Q1, THEN END SURVEY 
2. Are you currently licensed and actively practicing in this specialty? 
A. Yes 
B. No 
IF B SELECTED IN Q2, THEN END SURVEY 
3. What percent of your time is spent in the following activities? 
A. Direct outpatient care _______ %  (IF LESS THAN 25%, END SURVEY) 
B. Hospital inpatient care _______ %  (IF MORE THAN 50%, END SURVEY) 
C. Administrative activities, teaching, or research _______ %  (IF MORE THAN 
50%, END SURVEY) 
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IF THE RESPONDENT HAS SATISFACTORILY ANSWERED THE PREVIOUS THREE 
QUESTIONS, THEY ARE ELIGIBLE FOR THE FULL SURVEY  
 
4. In what state do you primarily practice?  
_________________ 
CAPTURE AT LEAST 20 PEOPLE FROM EACH REGION BELOW IN Q4 
Midwest (Ohio, Indiana, Michigan, Illinois, Missouri, Wisconsin, Minnesota, Iowa, Kansas, Nebraska, South 
Dakota, North Dakota) 
Northeast (Maine, Massachusetts, Rhode Island, Connecticut, New Hampshire, Vermont, New York, 
Pennsylvania, New Jersey, Delaware, Maryland) 
Southeast (West Virginia, Virginia, Kentucky, Tennessee, North Carolina, South Carolina, Georgia, Alabama, 
Mississippi, Arkansas, Louisiana, Florida) 
Southwest (Texas, Oklahoma, New Mexico, Arizona) 
West (Colorado, Wyoming, Montana, Idaho, Washington, Oregon, Utah, Nevada, California, Alaska, Hawaii) 
5. How many years have you been in practice since finishing your residency? 
A. Less than 5 
B. 5 – 15 
C. 16 – 25 
D. More than 25 
 
6. Which of the following most closely represents your current professional status? 
A. Practice owner/partner/associate 
B. Employed by a hospital or health system 
C. Employed by a medical group 
D. Employed by a university hospital or health system 
E. Other 
 
7. Is your practice: 
A. Solo 
B. 2 – 5 physicians 
C. 6 – 10 physicians 
D. 11 – 30 physicians 
E. 31 – 100 physicians 
F. 101 or more physicians 
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8. How many physicians, including you, work in your main primary care practice location 
(the location where you spend most of your time during the week)?  
__________________ physicians 
9. Is your primary care practice located in a single specialty or multi-specialty practice?     
(multi-specialty practice includes physician specialists other than primary care) 
A. Single specialty 
B. Multi-specialty 
 
10. What percentage of your practice is staffed by non-physician advanced practice 
providers? (e.g. nurse practitioners and physician assistants) 
________________% 
 
11. On average, what is your best estimate for the number of patients you see per day in your 
primary care practice? 
___________________ patients 
12. Which of the following options best describes pharmacist involvement with your primary 
care practice? 
A. Full-time staff pharmacist that works in your primary care practice 
B. Part-time staff or consultant pharmacist that works in your primary care practice  
C. I only have interactions with community pharmacists not employed in my primary 
care practice (i.e., independent, chain, retail, grocery-store pharmacies) 
D. Other; please describe _____________________________ 
 
13. How important, to you, is collaborating with a pharmacist for the care of patients in your 
primary care practice? 
Not at all 
important 
Slightly 
important 
Somewhat 
important 
Moderately 
important 
Extremely 
important 
1 2 3 4 5 
 
14. Please rate your level of familiarity with formal collaborative practice agreements 
between physicians and pharmacists. 
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Not at all 
familiar 
Slightly 
familiar 
Somewhat 
familiar 
Moderately 
familiar 
Extremely 
familiar 
1 2 3 4 5 
 
 
SHOW THIS STATEMENT TO ALL RESPONDENTS AFTER Q14.  
 
❖ Collaborative practice agreements (CPAs) are used to create formal relationships between 
pharmacists and physicians, or other providers. This allows the pharmacist to provide 
expanded clinical services to patients and the healthcare team.  
❖ CPAs define certain patient care functions that a pharmacist can autonomously provide 
under specified situations and conditions. Of important note, CPAs are not required for 
pharmacists to perform many patient care services (e.g., medication reviews, patient 
education and counseling, disease screening).  
❖ A CPA allows qualified pharmacists to assume professional responsibility for performing 
patient assessments and making referrals, ordering and reviewing laboratory tests, 
administering medications, and selecting, initiating, monitoring, continuing, and 
adjusting medication regimens. 
❖ References – (https://www.aphafoundation.org/collaborative-practice-agreements, 
https://www.cdc.gov/dhdsp/pubs/guides/best-practices/pharmacist-cdtm.htm)  
 
15. Is pharmacist involvement in your primary care practice part of a collaborative practice 
agreement (CPA)? 
A. Yes 
B. No 
C. Not sure 
IF A SELECTED IN Q15, SHOW Q16 
16. What level of access do pharmacists have to patient medical records in your main 
primary care practice location? 
A. Full access 
B. Limited access (e.g., only medication related information) 
C. No access 
 
 
 
 
 
152 
 
Part B. Clinical pharmacogenomics 
The questions in this section will help us better understand your experience with and 
perspectives on clinical pharmacogenomics.  
17. Please rate your familiarity with using clinical pharmacogenomic information. 
Not at all 
familiar 
Slightly 
familiar 
Somewhat 
familiar 
Moderately 
familiar 
Extremely 
familiar 
1 2 3 4 5 
 
SHOW THIS STATEMENT TO ALL RESPONDENTS AFTER Q15.   
 
❖ Clinical pharmacogenomics is the application of pharmacogenomics, a field of medicine 
that studies how individual genetic differences may govern drug toxicity and/or response, 
for use in clinical practice.  
❖ Pharmacogenomics can be classified as either germline pharmacogenomics, which refers 
to the study of how inherited genomic variants influence alterations in a medication’s 
pharmacokinetic and pharmacodynamic properties, or somatic pharmacogenomics, which 
studies how acquired genomic variants influence medication response (e.g. cancers and 
infectious disease).  
❖ Diagnostic testing to identify these genomic variants includes single-gene testing, multi-
gene panel testing, and sequencing. This can be done either reactively, ordering a test 
when a patient is likely to be prescribed a drug with pharmacogenomic implications, or 
preemptively, independent of whether the patient is receiving a medication or not. 
❖ References – Borden et al., Pharmacogenomics J 2019, Relling and Evans, Nature 2015. 
Please rate your level of agreement with the following statements.  
18. Clinical pharmacogenomics meets my approval 
 
 
 
 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
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19. Clinical pharmacogenomics is appealing to me 
 
20. I like clinical pharmacogenomics 
21. I welcome clinical pharmacogenomics 
 
Please rate your level of agreement with the following statements.  
22. Clinical pharmacogenomics seems fitting in my primary care practice 
 
23. Clinical pharmacogenomics seems suitable for my primary care practice 
 
 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
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24. Clinical pharmacogenomics seems applicable to my primary care practice 
 
25. Clinical pharmacogenomics seems like a good match for my primary care practice 
 
Please rate your level of agreement with the following statements.  
26. Clinical pharmacogenomics seems implementable in my primary care practice  
 
27. Clinical pharmacogenomics seems possible for my primary care practice 
 
28. Clinical pharmacogenomics seems doable in my primary care practice 
 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
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29. Clinical pharmacogenomics seems easy to use at primary care practice 
 
 
Please read the following scenario carefully and answer the questions that follow based on 
the scenario.  
RESPONDENTS SHOWN ONLY ONE VIGNETTE – EQUAL QUOTA PER VIGNETTE  
Vignette #1 - You have a collaborative practice agreement with a clinical pharmacist who works 
in your primary care clinic. This pharmacist operates under a defined protocol that allows them 
to work autonomously at higher levels of clinical practice. In addition to their medication therapy 
management duties, this pharmacist may initiate, continue, modify, or discontinue medications, 
order and review laboratory tests, and make referrals to other medical providers. 
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in 
your primary care clinic would look like this. 
▪ The collaborative practice clinical pharmacist provides services while being 
physically located in your primary care clinic. 
▪ This clinical pharmacist is responsible for selecting and ordering the 
pharmacogenomic test for the patient. 
▪ The clinical pharmacist manages the return of results and prepares a report for the 
patient’s medical record. The report includes the results and the potential implications 
on all relevant medication therapy. 
▪ The clinical pharmacist is also responsible for making any appropriate modifications 
to the patient’s medication regimen considering the pharmacogenomic information 
now available. 
 
Vignette #2 - You have a collaborative practice agreement with a local pharmacy that provides 
pharmacogenomic services. The clinical pharmacists operate under a defined protocol that allows 
them to work autonomously at higher levels of clinical practice. In addition to their medication 
therapy management duties, these pharmacists may initiate, continue, modify, or discontinue 
medications, order and review laboratory tests, and make referrals to other medical providers. 
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in 
your primary care clinic would look like this. 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
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▪ The collaborative practice clinical pharmacist provides services while not being 
physically located in your primary care clinic. 
▪ This clinical pharmacist is responsible for selecting and ordering the 
pharmacogenomic test for the patient. 
▪ The clinical pharmacist manages the return of results and prepares a report for the 
patient’s medical record. The report includes the results and the potential implications 
on all relevant medication therapy. 
▪ The clinical pharmacist is also responsible for making any appropriate modifications 
to the patient’s medication regimen considering the pharmacogenomic information 
now available. 
 
Vignette #3 - You have a collaborative practice agreement with a clinical pharmacist who works 
in your primary care clinic. This pharmacist operates under a defined protocol that allows them 
to work autonomously at higher levels of clinical practice. In addition to their medication therapy 
management duties, this pharmacist may initiate, continue, modify, or discontinue medications, 
and make referrals to other medical providers. 
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in 
your primary care clinic would look like this. 
▪ The collaborative practice clinical pharmacist provides services while being 
physically located in your primary care clinic. 
▪ You, the physician, are responsible for selecting and ordering the pharmacogenomic 
test for the patient. 
▪ The clinical pharmacist manages the return of results and prepares a report for the 
patient’s medical record. The report includes the results and the potential implications 
on all relevant medication therapy. 
▪ The clinical pharmacist is also responsible for making any appropriate modifications 
to the patient’s medication regimen considering the pharmacogenomic information 
now available. 
 
Vignette #4 - You have a collaborative practice agreement with a local pharmacy that provides 
pharmacogenomic services. The clinical pharmacists here operate under a defined protocol that 
allows them to work autonomously at higher levels of clinical practice. In addition to their 
medication therapy management duties, these pharmacists may initiate, continue, modify, or 
discontinue medications, and make referrals to other medical providers. 
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in 
your primary care clinic would look like this. 
▪ The collaborative practice clinical pharmacist provides services while not being 
physically located in your primary care clinic. 
▪ You, the physician, are responsible for selecting and ordering the pharmacogenomic 
test for the patient. 
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▪ The clinical pharmacist manages the return of results and prepares a report for the 
patient’s medical record. The report includes the results and the potential implications 
on all relevant medication therapy. 
▪ The clinical pharmacist is also responsible for making any appropriate modifications 
to the patient’s medication regimen considering the pharmacogenomic information 
now available. 
 
Vignette #5 - You have a collaborative practice agreement with a clinical pharmacist who works 
in your primary care clinic. This pharmacist operates under a defined protocol that allows them 
to work autonomously at higher levels of clinical practice. In addition to their medication therapy 
management duties, this pharmacist may order and review laboratory tests, and make referrals to 
other medical providers. 
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in 
your primary care clinic would look like this. 
▪ The collaborative practice clinical pharmacist provides services while being 
physically located in your primary care clinic. 
▪ The clinical pharmacist is responsible for selecting and ordering the 
pharmacogenomic test for the patient. 
▪ You, the physician, manage the return of results and prepare a report for the patient’s 
medical record. The report includes the results and the potential implications on all 
relevant medication therapy. 
▪ You are also responsible for making any appropriate modifications to the patient’s 
medication regimen considering the pharmacogenomic information now available. 
 
Vignette #6 - You have a collaborative practice agreement with a local pharmacy that provides 
pharmacogenomic services. The clinical pharmacists here operate under a defined protocol that 
allows them to work autonomously at higher levels of clinical practice. In addition to their 
medication therapy management duties, these pharmacists may order and review laboratory tests, 
and make referrals to other medical providers. 
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in 
your primary care clinic would look like this. 
▪ The collaborative practice clinical pharmacist provides services while not being 
physically located in your primary care clinic. 
▪ The clinical pharmacist is responsible for selecting and ordering the 
pharmacogenomic test for the patient. 
▪ You, the physician, manage the return of results and prepare a report for the patient’s 
medical record. The report includes the results and the potential implications on all 
relevant medication therapy. 
▪ You are also responsible for making any appropriate modifications to the patient’s 
medication regimen considering the pharmacogenomic information now available. 
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Vignette #7 - You have a collaborative practice agreement with a clinical pharmacist who works 
in your primary care clinic during the week. This pharmacist operates under a defined protocol 
that allows them to work autonomously at higher levels of clinical practice. In addition to their 
medication therapy management duties, this pharmacist may make referrals to other medical 
providers. 
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in 
your primary care clinic would look like this. 
▪ The collaborative practice clinical pharmacist provides services while being 
physically located in your primary care clinic. 
▪ You, the physician, are responsible for selecting and ordering the pharmacogenomic 
test for the patient. 
▪ You manage the return of results and prepare a report for the patient’s medical record. 
The report includes the results and the potential implications on all relevant 
medication therapy. 
▪ You are also responsible for making any appropriate modifications to the patient’s 
medication regimen considering the pharmacogenomic information now available. 
 
Vignette #8 - You have a collaborative practice agreement with a local pharmacy that provides 
pharmacogenomic services. The clinical pharmacists here operate under a defined protocol that 
allows them to work autonomously at higher levels of clinical practice. In addition to their 
medication therapy management duties, these pharmacists may make referrals to other medical 
providers. 
With this collaborative practice agreement in place, delivering clinical pharmacogenomics in 
your primary care clinic would look like this. 
▪ The collaborative practice clinical pharmacist provides services while not being 
physically located in your primary care clinic. 
▪ You, the physician, are responsible for selecting and ordering the pharmacogenomic 
test for the patient. 
▪ You manage the return of results and prepare a report for the patient’s medical record. 
The report includes the results and the potential implications on all relevant 
medication therapy. 
▪ You are also responsible for making any appropriate modifications to the patient’s 
medication regimen considering the pharmacogenomic information now available. 
 
Please rate your level of agreement with the following statements based on the previous 
scenario. 
30. Clinical pharmacogenomics delivered this way seems fitting in my primary care practice 
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31. Clinical pharmacogenomics delivered this way seems suitable for my primary care 
practice 
 
32. Clinical pharmacogenomics delivered this way seems applicable to my primary care 
practice 
 
33. Clinical pharmacogenomics delivered this way seems like a good match for my primary 
care practice 
 
 
 
 
 
 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
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Please rate your level of agreement with the following statements based on the previous 
scenario. 
34. Clinical pharmacogenomics delivered this way seems implementable in my primary care 
practice  
 
35. Clinical pharmacogenomics delivered this way seems possible for my primary care 
practice 
 
36. Clinical pharmacogenomics delivered this way seems doable in my primary care practice 
 
37. Clinical pharmacogenomics delivered this way seems easy to use at primary care practice 
 
For the remaining questions, you do not need to consider the information presented in the 
previous scenario. 
38. In your opinion, what is biggest barrier to more widespread use of clinical 
pharmacogenomics in your primary care practice? 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
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A. Physician education in the appropriate use of pharmacogenomics 
B. Patient interest and engagement 
C. Insurance coverage and affordability 
D. Evidence base to support routine use of pharmacogenomics 
E. Electronic health record tools for pharmacogenomics 
 
39. If prescribing and ordering a pharmacogenomic test were not part of your clinical 
workflow, and the information was readily available in your patient’s medical record at 
the point of prescribing, would this make the delivery of clinical pharmacogenomics 
more feasible?  
A. Yes 
B. No 
 
40. On average, how often do patients ask you about pharmacogenomic testing? 
a) Every week 
b) Every month 
c) Every 6 months 
d) I have never been asked about pharmacogenomic testing by a patient 
 
41. On average, how often do you use pharmacogenomic information in the care of specific 
patients? 
a) Every week 
b) Every month 
c) Every 6 months 
d) I have never used pharmacogenomic information 
 
Please rate your level of agreement with the following statements: 
42. I am confident in my ability to use the results of a pharmacogenomic test.  
 
 
 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
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43. My training has prepared me to treat patients whose genetics place them at high risk for 
medical conditions. 
 
44. I can find/use reliable sources of the information I need to apply pharmacogenomic 
testing while caring for patients 
 
Please rate your level of familiarity with the following pharmacogenomic resources. 
45. CPIC – The Clinical Pharmacogenetics Implementation Consortium 
Not at all 
familiar 
Slightly 
familiar 
Somewhat 
familiar 
Moderately 
familiar 
Extremely 
familiar 
1 2 3 4 5 
 
46. PharmGKB – Pharmacogenomics Knowledgebase 
Not at all 
familiar 
Slightly 
familiar 
Somewhat 
familiar 
Moderately 
familiar 
Extremely 
familiar 
1 2 3 4 5 
 
 
 
 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
Strongly 
disagree 
Tend to 
disagree 
Neither agree 
nor disagree 
Tend to agree Strongly agree 
1 2 3 4 5 
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APPENDIX 2. SUMMARY OF RESULTS PROVIDED TO RESPONDING 
PHYSICIANS 
TITLE: Sustainable Delivery of Pharmacogenomics in Primary Care: Testing the Potential for 
Physician-Pharmacist Collaboration 
PURPOSE 
Advancement in the clinical implementation of pharmacogenomics can be largely attributed to 
numerous large-scale academic research programs over the past decade. Most of these programs 
utilize a transdisciplinary model of physician-pharmacist collaboration for delivering 
pharmacogenomics. Drawing from literature showing improved outcomes from such 
collaborations, the successes of ongoing implementation programs, and theoretical work from 
the field of implementation science, this study sets out to experimentally test this collaboration in 
the primary care setting.  
METHODS 
This study utilized a 2x2x2 between-subjects experimental design with data collected using an 
online survey and hypothetical vignettes. Responses were received from 176 US-based primary 
care physicians (PCPs). Primary outcome measures: Intervention Appropriateness Measure 
(IAM) and Feasibility of Intervention Measure (FIM). Manipulated vignette factors: location of 
the pharmacist (in clinic vs. not), who selects and orders the test (pharmacist vs. physician), and 
who manages and modifies the medication regimen (pharmacist vs. physician). 
RESULTS                                      
The main effects on the IAM were not statistically significant at α <0.05. However, the two-way 
interaction effect between location and who manages and modifies the medication regimen was 
statistically significant (p=0.04). Although not statistically significant, a second potential 
crossover interaction effect was observed between location and who selects and orders the test 
(p=0.09). Results of the manipulations on the FIM scale showed no significance of the main 
effects or interactions, but a non-significant crossover interaction was observed between location 
and who manages and modifies the medication regimen (p=0.09).  
CONCLUSIONS                      
PCPs find the delivery of pharmacogenomics significantly more appropriate for their practice 
when the pharmacist is managing and modifying the patient’s medication regimen while located 
in the clinic. PCPs responded that this same scenario would likely be more feasible. There is also 
evidence that it is more appropriate for the pharmacist to select and order the test when located in 
the clinic.  
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General Practice Characteristics Frequency  (%) 
Primary medical specialty  
     Family Medicine 111  (63%) 
     Internal Medicine 65  (37%) 
Region  
     Midwest 50  (28%) 
     West 31  (18%) 
     Southwest 20  (11%) 
     Northeast 33  (19%) 
     Southeast 42  (24%) 
Years in practice  
     Less than 5 4  (2%) 
     5 – 15  20  (11%) 
     16 – 25 68  (39%) 
     More than 25 84  (48%) 
Professional status  
     Practice owner/partner/associate 91  (52%) 
     Employed by hospital or health system 43  (24%) 
     Employed by medical group 31  (18%) 
     Employed by a university hospital or health system 9  (5%) 
     Other 2  (1%) 
Size of practice (# of physicians)  
     Solo 43  (24%) 
     2 – 5  58  (33%) 
     6 – 10  25  (14%) 
     11 – 30  18  (10%) 
     31 – 100 16  (9%) 
     More than 100 16  (9%) 
Single or multi-specialty clinic  
     Single specialty 119  (68%) 
     Multi-specialty 57  (32%) 
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Pharmacist related practice characteristics Mean 
Importance of collaborating with pharmacist for care of patients in the 
primary care practice 
(1 = Not at all important, 5 = Very important) 
3.47 
Familiarity with CPAs between physicians and pharmacists 
(1 = Not at all familiar, 5 = Very familiar) 
2.50 
 Frequency (%) 
Pharmacist involvement in practice  
     Full-time staff that works in the clinic 23  (13%) 
     Part-time staff or consultant that works in the clinic 16  (9%) 
     Only interacts with community pharmacist not employed by practice 134  (76%) 
Pharmacist involvement is part of a CPA  
     Yes 27  (15%) 
     No 124  (70%) 
     Not sure 25  (14%) 
Level of CPA pharmacist access to patient medical records (n=27)  
     Full access 23  (85%) 
     Limited access (e.g. only medication related information) 4  (15%) 
 
Pharmacogenomics familiarity  
(1 = Not at all familiar, 5 = Very familiar) 
Mean 
Familiarity with using clinical pharmacogenomic information 2.63 
Familiarity with CPIC 1.61 
Familiarity with PharmGKB 1.59 
Pre-implementation Provider Items from IGNITE Spark Toolbox 
(1 = Strongly disagree, 5 = strongly agree) 
“I am confident in my ability to use the results of a pharmacogenomic 
test” 
3.18 
“My training has prepared me to treat patients whose genetics place them 
at a high risk for medical conditions” 
2.96 
“I can find/use reliable sources of the information I need to apply 
pharmacogenomic testing while caring for patients” 
3.18 
Use of  pharmacogenomics in practice Frequency  (%) 
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Frequency with which patients ask PCP about pharmacogenomic testing  
Every week 6  (3%) 
Every month 20  (11%) 
Every six months 34  (19%) 
Never been asked about it 116  (66%) 
Frequency with which PCPs use pharmacogenomic information in the 
care of specific patients 
 
Every week 11 (6%) 
Every month 29 (16%) 
Every six months 40 (23%) 
Never been asked about it 96  (55%) 
Biggest barrier to more widespread use of pharmacogenomics in their 
primary care practice 
 
Physicians knowledge regarding appropriate use 33  (19%) 
Patient interest and engagement 11  (6%) 
Insurance coverage and affordability 93 (53%) 
Evidence base to support routine use of pharmacogenomics 34  (19% 
Electronic health record tools for pharmacogenomics 5  (3%) 
Pharmacogenomics more feasible if prescribing and orderings were not 
part of clinical workflow, and information was already in medical record 
 
Yes 143  (81%) 
No 33  (19%) 
 
Implementation Outcome Measures Applied to Clinical 
Pharmacogenomics  
(1 = Strongly disagree, 5 = Strongly Agree) 
Mean (SD) 
Acceptability of Intervention Measure (AIM)  
Clinical pharmacogenomics meets my approval 3.72 
Clinical pharmacogenomics is appealing to me 3.77 
I like clinical pharmacogenomics 3.62 
I welcome clinical pharmacogenomics 3.73 
Overall Mean = 3.71  
Intervention Appropriateness Measure (IAM)  
Clinical pharmacogenomics seems fitting in my primary care practice 3.45 
Clinical pharmacogenomics seems suitable for my primary care practice 
3.48 
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Clinical pharmacogenomics seems applicable to my primary care practice 
3.60 
Clinical pharmacogenomics seems like a good match for my primary care  
practice 3.49 
Overall Mean = 3.50 
Feasibility of Intervention Measure (FIM)  
Clinical pharmacogenomics seems implementable in my primary care 
practice 3.19 
Clinical pharmacogenomics seems possible for my primary care practice 
3.54 
Clinical pharmacogenomics seems doable in my primary care practice 
3.36 
Clinical pharmacogenomics seems easy to use at my primary care practice 
2.99 
Overall Mean = 3.27 
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APPENDIX 3. DEMOGRAPHIC AND PRACTICE CHARACTERISTICS 
General Practice Characteristics Percentage of respondents 
Primary medical specialty  
     Family Medicine 63% 
     Internal Medicine 37% 
Region  
     Midwest 28% 
     West 18% 
     Southwest 11% 
     Northeast 19% 
     Southeast 24% 
Years in practice  
     Less than 5 2% 
     5 – 15  11% 
     16 – 25 39% 
     More than 25 48% 
Professional status  
     Practice owner/partner/associate 52% 
     Employed by hospital or health system 24% 
     Employed by medical group 18% 
     Employed by a university hospital or health system 5% 
     Other 1% 
Size of practice (# of physicians)  
     Solo 24% 
     2 – 5  33% 
     6 – 10  14% 
     11 – 30  10% 
     31 – 100 9% 
     More than 100 9% 
Single or multi-specialty clinic  
     Single specialty 68% 
     Multi-specialty 32% 
Table 1. Practice characteristics among all respondents 
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Pharmacist related practice characteristics Mean 
Importance of collaborating with pharmacist for care of patients in the 
primary care practice 
(1 = Not at all important, 5 = Very important) 
3.47 
Familiarity with CPAs between physicians and pharmacists 
(1 = Not at all familiar, 5 = Very familiar) 
2.50 
 
Percentage of 
respondents 
Pharmacist involvement in practice  
     Full-time staff that works in the clinic 13% 
     Part-time staff or consultant that works in the clinic 9% 
     Only interacts with community pharmacist not employed by practice 76% 
Pharmacist involvement is part of a CPA  
     Yes 15% 
     No 70% 
     Not sure 14% 
Level of CPA pharmacist access to patient medical records (n=27)  
     Full access 85% 
     Limited access (e.g. only medication related information) 15% 
Table 2. Pharmacist related practice characteristics among all respondents 
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Pharmacogenomics related questions  
Pharmacogenomics familiarity  
(1 = Not at all familiar, 5 = Very familiar) 
Mean 
Familiarity with using clinical pharmacogenomic information 2.63 
Familiarity with CPIC 1.61 
Familiarity with PharmGKB 1.59 
Pre-implementation Provider Items from IGNITE Spark Toolbox 
(1 = Strongly disagree, 5 = strongly agree) 
“I am confident in my ability to use the results of a pharmacogenomic 
test” 
3.18 
“My training has prepared me to treat patients whose genetics place them 
at a high risk for medical conditions” 
2.96 
“I can find/use reliable sources of the information I need to apply 
pharmacogenomic testing while caring for patients” 
3.18 
Use of  pharmacogenomics in practice 
Percentage of 
respondents 
Frequency with which patients ask PCP about pharmacogenomic testing  
Every week 3% 
Every month 11% 
Every six months 19% 
Never been asked about it 66% 
Frequency with which PCPs use pharmacogenomic information in the 
care of specific patients 
 
Every week 6% 
Every month 16% 
Every six months 23% 
Never used it 55% 
Biggest barrier to more widespread use of pharmacogenomics in their 
primary care practice 
 
Physicians knowledge regarding appropriate use 19% 
Patient interest and engagement 6% 
Insurance coverage and affordability 53% 
Evidence base to support routine use of pharmacogenomics 19% 
Electronic health record tools for pharmacogenomics 3% 
Pharmacogenomics more feasible if prescribing and ordering were not 
part of clinical workflow 
 
Yes 81% 
No 19% 
Table 3. Pharmacogenomic related practice characteristics across all respondents
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CONCLUSION 
 We have designed and completed three complementary research studies focused on the 
clinical implementation of pharmacogenomic testing and the factors contributing to the 
sustainability of the science within its current environment and its sustainability in future 
settings. Theory guiding this work has been taken from the discipline of implementation science 
and one of its foundational concepts, sustainability. Public health organizations in the US 
including the Centers for Disease Control and Prevention (CDC) and the National Institutes of 
Health (NIH) have been leading this call.1,2 The National Cancer Institute (NCI) at the NIH has 
been particularly strong in its advocacy of implementation science more generally and not just in 
genomics.3 The issue of translating evidence-based research into clinical application reaches all 
corners of medicine, including pharmacogenomics, and thus the more formal integration of 
implementation science principles is warranted. These three studies will also continue building 
the ongoing relationship between implementation science and genomic medicine. Additionally, 
the two primary data collection studies are the first to formally apply an implementation science 
framework or implementation science outcomes to the field of pharmacogenomics. 
 The scoping review study began this three-part work with an examination of the extent to 
which previous research has explicitly assessed health care provider interactions with and use of 
pharmacogenomics in hypothetical or real-world practice. While this study did not apply a 
certain implementation science framework, as in the qualitative piece, the Dynamic 
Sustainability Framework (DSF) provides the reader with a reflection on the importance of field 
conducting such studies. In the introduction we mentioned two tenets of the DSF: “interventions 
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can be continually improved, specific to each setting” and “ongoing feedback is essential and 
should be measured over time”.4 These thoughts helped tighten our research question to make 
this study unique and an important contribution to the literature. The literature has seen a great 
deal of work targeted to understand the perceptions and opinions of providers toward the use of 
pharmacogenomics, however cross-sectional studies of this nature miss the mark when we look 
at those two tenets of the DSF.5-8 It is methodologies found in the studies included in the scoping 
review that position implementers to be able to continually improve and assess feedback from 
the actual experience using a new intervention such as pharmacogenomic testing.  
  Most of the 25 studies included in our scoping review were published between 2015 and 
2018 on the North American and European continents. This was over double the number of 
studies published the previous five-year block (2010-2014) and demonstrates a promising trend 
that researchers and implementers are recognizing the importance of such methodologies. It 
would be intriguing to compare these results with the publication trends of studies that only 
assess perceptions or opinions regarding pharmacogenomics. We found that the largest number 
of included studies were those using hypothetical clinical case scenarios closely followed by 
real-world studies regarding prescribing and testing decisions. Many of these studies were 
focused on evaluating the clinical decision support (CDS) systems that enable providers to 
deliver timely and clinically relevant pharmacogenomic information to patients.9 While 
understanding how providers interacted with these systems was important, several studies also 
aimed to measure the adherence or compliance physicians had to the recommendations of their 
human colleagues, pharmacists, regarding medication use in light of genomic information. In 
only one study was the pharmacist the primary respondent for data collection, but in many in 
they were responsible for the clinical action the physician was acting on.10 In fact, some of the 
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more robustly designed studies were those with the pharmacists at the center of the research 
question.10,11 The discussion over who should be responsible for managing pharmacogenomic 
results and delivery of information to the patient is ongoing.  
The choice to focus on methodology in this review was appropriate for the field 
currently. As researchers look to answer questions about the best way to deliver 
pharmacogenomic CDS or which provider is best for delivery this information to patients, the 
illuminating findings from this study should give future researchers a firm and broad baseline 
assessment of methodologies to carry forward and build upon. Understanding the methods of 
current researchers and implementers and their historical applications will hopefully create a 
sustainable future for clinical pharmacogenomics.  
 The second research study herein was the most explicit of the three in its use of 
implementation science to guide the research design and data collection. Researchers in the 
IGNITE group have led the way with their previous research on genomic medicine and 
implementation science.12,13 The work of the Common Measures working group was 
instrumental in the decision to pursue a focus on the Process domain. Further, the application of 
the Process domain was strengthened by the identification of several highly ranked constructs of 
importance to the sustainability of genomic medicine. The connection between the foundational 
concept of sustainability and the Process domain is underpinned by the operational indicator of 
sustainability, capacity building. Previous research conceptualized this not only as a physical 
indicator, but human as well.14 The constructs and sub-constructs of the Process domain use 
almost identical language as some of the factors represented by these physical and human 
infrastructures in previous literature.15,16 
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 The findings from this study demonstrated a strong focus throughout on effective 
communication as a facilitator of success across many of the constructs and sub-constructs. The 
Planning construct involved numerous discussions on the need to understand the existing interest 
and testing volume prior to implementing. This was a crucial factor for many as it determined a 
first gene-drug pair implementation target and the desire to get an “early-win” for their program. 
The Engaging construct, more than any other construct, dealt with the human capacity building 
indicator of sustainability. Cutting across several types of essential personnel, this construct 
provided more nuance on the influence certain individuals or types of individuals had on 
colleagues and the success of the program. The importance of quick, frequent, and informal 
interactions with providers cannot be understated. This was one of the most ubiquitous findings 
in the whole study. The Reflecting & Evaluating construct showed that the goals of most of this 
early adopter programs was simply to provide pharmacogenomics to the patients. Patient safety 
was cited several times a primary driver of this goal. Outcomes based studies are planned in the 
future for many of the participant institution, but at this time process metrics and structured 
provider feedback make up most data collection. 
 This research represents one the first formal applications of an implementation science 
framework to the study of clinical pharmacogenomics. Further, we have tied the formal use of 
such a framework to the one of its discipline’s foundational concepts, sustainability, and the 
identified constructs necessary to achieve that in genomic medicine. As evidenced herein by the 
ongoing challenges among pioneers in the implementation of pharmacogenomics, sustainability 
is not just an economic construct related to coverage and reimbursement policies. Successfully 
sustaining pharmacogenomics within participant institutions and designing future 
implementations with a mindset of sustainability will require precision targeting of supportive 
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administration and clinicians, maintaining dedicated IT support throughout, and remaining 
resilient in the face of inevitable failures. 
 The final study of this three-part work explored more deeply the topic that we have 
already discussed in each of the two previous studies. That is, the question of which health care 
providers are best positioned to deliver care using pharmacogenomic information. The scoping 
review included one study that investigated whether specialists or primary care providers should 
carry this responsibility, but the larger discussion has centered on what level of involvement the 
pharmacist should have in conducting pharmacogenomic testing and the interpretation of 
results.11,17,18 Pharmacist involvement to date in the implementation of clinical 
pharmacogenomic programs at major academic institutions has been robust. However, there has 
been little investigation into how the pharmacist’s skill set can be utilized in a primary care 
setting and what is the attitude of primary care physicians towards their use.19,20 To understand 
this more fully, we applied three validated implementation science outcome measures 
(acceptability, appropriateness, feasibility) that were created to enable more standardized 
assessments of conceptualizing and evaluating the success of an intervention.21,22  
 Results from our cross-sectional survey indicated that primary care physicians were 
accepting of pharmacogenomics but the feasibility of delivering it in their practice produced 
somewhat lower scores. Using an experimental vignette methodology, in the second portion of 
the survey we explored the appropriateness and feasibility of delivering pharmacogenomics in a 
collaborative practice agreement across different levels of pharmacist responsibility. We tested 
three main effects: location of the pharmacist (in or out of the clinic), provider responsible for 
selecting and ordering the test (pharmacist or physician), and the provider responsible for 
managing results and modifying drug therapy (pharmacist or physician). When the pharmacist 
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was responsible for managing pharmacogenomic results and modifying drug therapy, primary 
care physicians found this to be more appropriate when the pharmacist was physically located in 
the clinic. Also, although not statistically significant at α=0.05, the same scenario just described 
was seen as more feasible according to our sample of primary care physicians. Lastly, when the 
pharmacist was located in the clinic, physicians were indifferent regarding the appropriateness of 
themselves or the pharmacist selecting and ordering the pharmacogenomic test.  
 This study builds on previous pilot work that tested the effects of pharmacist integration 
into a primary care practice on testing volume and utilization of pharmacist consult.11 However, 
we have produced results with broader generalizability because the investigation was not 
restricted to one geographic set of primary care practices. These results clearly show that primary 
care physicians are willing to give up some clinical autonomy to the pharmacist to enable 
delivery of pharmacogenomics in clinical practice. The ability for this to succeed will also be 
partially dependent on robust educational and training initiatives that enable the pharmacist to 
effectively deliver pharmacogenomic testing. Finally, variability in state-to-state collaborative 
practice policies should be examined as a crucial factor in the success of such arrangements. 
Physicians in states with more advanced policies will likely be the innovators in advancing the 
pharmacist to higher levels of clinical practice, while laggard state policies will require greater 
intervention and education on the benefits and possibilities of such arrangements. 
 To close, these three studies have focused on converging the clinical science of 
pharmacogenomics with the discipline of implementation science. We have more deeply 
explored this convergence by looking at the foundation concept of sustainability. This work has 
great methodological breadth as we utilized review, qualitative, and quantitative/experimental 
techniques. Moving forward the hope is that future researchers recognize the potential for 
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implementation science as a facilitator of high quality, standardized study designs that address 
new and existing issues critical to the sustainability of clinical pharmacogenomics in practice.   
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